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Abstract 
Background: Substance abuse is a chronic disease often characterized by 
multiple attempts at abstinence, frequent relapse and is associated with a range of 
morbidities and mortality. This dissertation utilizes a mobile health (mHealth) 
data collection method known as Ecological Momentary Assessment (EMA) to 
capture the dynamic process that drug use represents. The goals of this 
dissertation were to examine the accuracy of real-time mHealth methods in 
assessing drug use, examine individual drug using patterns to identify those at 
risk for poor engagement in care and to examine the real-time environments of 
drug using and craving.  
Methods: Exposure Assessment in Current Time (EXACT) study participants 
were recruited from the AIDS Linked to the IntraVenous Experience (ALIVE) 
study, an on-going, community-recruited, observational cohort of persons with a 
history of injecting drugs in Baltimore, MD. The EXACT study included four 
successive trials, planned to follow 30 participants each for 30 days and was 
conducted from November 2008 through May 2013. Participants were asked to 
self-initiate a survey and self-report through a hand-held device each time they 
either craved (but refrained from using) or used heroin or cocaine (or both) in any 
manner (smoked, snorted or injected). At the end of each week, sweat patch 
samples (PharmCheck®) were collected for measurement of illicit substances and 
participants answered an audio-computer assisted self -interview (ACASI) 
questionnaire concerning activities, behaviors and drug using events during the 
prior week.  
Results: 109 EXACT participants were a median of 48.5 years old, 90% African 
American, 52% male and 59% HIV-infected. EMA methods demonstrated 
moderate percent agreement of reported drug use when compared to ACASI 
methods but less agreement when compared to sweat patch methods. Real-time 
collection of drug use identified three distinct classes of drug users. The most risky 
class included individuals engaging consistently in high-intensity drug using 
behavior, which was associated with poor engagement in care. Lastly, drug-related 
activities provided the strongest cues for real-time drug use, while craving was 
associated with being in more structured environments.   
Conclusion: Interactive mHealth methods are capable of assessing and describing 
the drug-using environment and can provide the framework for developing 
context-sensitive interventions (ecological momentary interventions) that can be 
tailored to prevent relapse and support cessation of illicit drug use. 
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Chapter 1: 
Introduction and Review of Literature
Background 
Substance abuse is a chronic disease often characterized by multiple attempts at 
abstinence with frequent relapse. Individuals with substance abuse problems tend 
to have a range of vulnerabilities that place them at increased risk for relapse as 
well as becoming HIV infected and failing to achieve the desired treatment 
outcome of viral suppression [1, 2]. People who inject drugs (PWID) are often 
poorly engaged in care due to multiple factors impeding their success [2], 
including continual risky drug using practices, HIV infection, hepatitis C 
infection, homelessness, depression, violence, poverty, incarceration, and poor 
treatment outcomes [1, 3, 4]. Yet, studies have found that among PWID capable 
of sustaining high levels of adherence can demonstrate positive HIV treatment 
outcomes [5].  
Identifying factors associated with drug use and relapse as well as understanding 
the pathways leading to drug use requires accurate exposure ascertainment 
methods. Self-reports of drug use are subject to socially desirable reporting. 
Despite substantial research, identification of the proximate predictors of relapse 
to illicit drug use, non-adherence to HIV medications, or to disengagement with 
primary care among drug users remains elusive. Understanding the dynamics of 
drug use (individual and situational) will aide in answering questions including: 
why are some active drug users able to maintain cessation and do well on HIV 
treatment while others have difficulty with drug relapse, ART non-adherence and 
virologic failure. 
 
Clinic-based, individualized support delivered by case managers or patient 
navigators has been shown to improve engagement in HIV care for many patients 
including PWID, but few settings have resources to offer such intensive treatment 
to all who need it [6]. Ecological momentary assessment (EMA) methods collect 
participant-level data in real time and facilitate responsive communication 
between providers and patients. EMA is a mobile health (mHealth) method that 
employs mobile devices (e.g., smartphones or other hand-held devices) to improve 
health outcomes, healthcare services and public health research. mHealth methods, 
such as Short Message Service (SMS) text messages have proven effective at 
increasing attendance at clinic appointments and improved adherence through 
antiretroviral (ART) dose reminder messages [7-12].  
 
Newer technologies are able to collect patient-level data in real time and facilitate 
responsive communication between clinic and patient. This dissertation utilizes 
data collected using ecological momentary assessments among a sample of drug 
users from the Exposure Assessment in Current Time (EXACT) study to examine 
the accuracy of real-time mHealth methods in assessing drug use, to identify 
individual drug using patterns to identify those at risk for poor engagement in 
treatment and care and to examine the real-time correlates of drug use and craving. 
 
Injection Drug use in the United States 
It has been estimated that approximately 16 million (range 11-21 million) 
individuals aged 15-64 years inject drugs worldwide [13]. In 2012, approximately 
7 million Americans aged 12 or older used cocaine or heroin in the past month and 
approximately 2 million Americans injected these drugs [14].  Needle sharing 
among persons who inject drugs (PWID) is a leading risk factor for the acquisition 
of HIV, hepatitis B and C as well as endocarditis and sepsis [15, 16].  Age-
adjusted mortality rates among PWID are estimated at 14 times that of non-
injection drug users, with deaths attributed to drug overdose, suicide, and AIDS-
related illness [17].  Homelessness, depression, violence, poverty, and 
incarceration are all associated with drug use, which often results in a loss of 
productivity, troubled families and unsafe communities [3, 18, 19]. 
 
Injection Drug Use in Baltimore, MD 
Baltimore City has one of the highest rates of PWID per capita in the United 
States [20].  It is estimated that 1 in 8 adults in Baltimore are heroin dependent and 
the city is ranked first in the nation for heroin and crack-related emergency room 
(ER) visits [21]. Surveillance data from 2012 reported 54% of prevalent HIV 
diagnoses were among injection drug users, making injection drug use the most 
common risk group for new diagnoses in Baltimore [22]. Currently, it is estimated 
that 1 in 10 African American males age 50-59 in Baltimore is living with HIV 
[22, 23].  
 
Disorder, Chaos and Injection Drug Use. 
Illicit drug use represents a dynamic process resulting from a complex interplay of 
factors occurring at multiple levels.  Persons affected by substance abuse often 
suffer from maladaptive, drug-seeking behaviors and material deprivation that put 
them at risk for acquiring several diseases, including HIV, hepatitis C (HCV) [24-
27] and tuberculosis [28, 29]. In addition to risky drug using behaviors, people 
who inject drugs are known to also engage in risky sexual behaviors, and suffer 
from high rates of depression [30-32] and alcohol dependence [32, 33]. These 
individual characteristics may be responsible for risk taking behaviors, however 
they do not explain all the inter-personal variability in risk behavior [34]. Aside 
from behavioral characteristics of drug users, substance abuse is also commonly 
associated with features of a chaotic or disordered life. This includes financial and 
legal difficulties as well as inadequate housing or transportation [35-37]. For 
example, a recent study demonstrated the relationship between levels of income 
inequality and the likelihood of fatal drug overdose [38]. 
 
Additional contextual factors associated with a disordered life and HIV risk 
behavior include situational factors (e.g., availability of services or employment 
and current emotional state), social norms and attitudes, and features of the 
physical environment (e.g. housing quality) [34].  Characteristics of 
neighborhoods have been shown to be important determinants of the health of 
drug users.  Recent research in Baltimore, MD examined the association between 
both neighborhood deprivation [39] and residential rehabilitation (defined as the 
percentage of residential properties where investment in interior or exterior 
maintenance exceeded $5000 USD for a given year)[40] on injection cessation. 
Continuous residence within neighborhoods with moderate/high rehabilitation and 
relocating to neighborhoods with moderate/high rehabilitation, were associated 
with a lower likelihood of injection drug use, while individuals who relocated 
from highly deprived to less deprived neighborhoods experienced a strong positive 
impact on long-term injection cessation.  
However, a primary challenge faced by neighborhood research is answering not 
just whether, but also how, the neighborhood influences drug use [41]. Few studies 
have assessed specific pathways from neighborhood environment to drug-related 
outcomes [42]. It has been suggested that macro-level neighborhood exposures, 
such as area-level deprivation, may be linked to drug-related outcomes through 
psychological and physiological stress [43, 44]. As a result, drugs are often used to 
relieve stress [42]. Previous research has shown that the level of psychological 
distress among residents partially mediated the observed relation between 
neighborhood deprivation and drug use in a sample of adults from Detroit [45]. 
Similarly, in Baltimore, injection drug users in more disordered neighborhoods 
have been shown to have higher levels of depression, and that this depression was 
associated with greater injection frequency [46]. 
 It has been postulated that intra-urban differences in the availability of illicit 
substances may be one of the key determinants linking neighborhood-level 
characteristics to individual drug-related outcomes. There are likely multiple 
pathways through which neighborhood-level factors influence drug use; the 
psychosocial environment and the local drug environment are both necessary to 
understand in order to know how neighborhood context influences drug-related 
outcomes. 
Drug craving has also been theorized to have a critical role in drug dependence 
and relapse, although there have been substantial inconsistences in data supporting 
this view [47, 48]. There is clear recognition of the need for more detailed and 
novel methods for measuring craving (e.g., a virtual reality approach has been 
used to examine cue-elicited tobacco cravings [49]).   
Despite much research concerning illicit drug use and its associated behaviors, 
novel strategies are needed to better understand the drug-using environment and to 
identify the proximate determinants of drug use of marginalized populations. 
Injection drug use, HIV and engagement in care 
The Health Resources and Services Administration (HRSA) propose a continuum 
of engagement in HIV care. According to HRSA, optimal HIV care includes early 
diagnosis of infection, prompt linkage to a regular source of care, appropriate 
initiation of antiretroviral therapy (ART), high levels of medication adherence and 
retention in care over the life course [50]. Adherence is defined as the percentage 
of prescribed pills taken by the patient, yet pill taking is only one of several 
behavioral factors of medication adherence. Active abuse of crack/cocaine has 
been associated with poor engagement in care and is commonly associated with 
features of a disordered life. Regardless of HIV status, engagement in health care 
entails specific actions that individuals must take to achieve the best outcomes from 
available health care services [51]; for example, having a primary care physician and 
regularly attending outpatient appointments rather than utilizing the emergency 
department for primary care needs (which is exceedingly expensive) . 
 
Previous clinic-based and community cohort studies of injection drug users 
showed the greatest risk factors for failure to suppress HIV RNA to be low social 
support [52] and missed clinic appointments [53], while ART use was 
independently associated with increases in patient-provider engagement, stable 
housing and a positive attitude about ART benefits, even if using illicit drugs [54]. 
Out-of-care people living with HIV/AIDS (PLWHA), particularly those who inject 
drugs, face several barriers that keep them from taking their medication regularly 
such as continued drug use, a lack of access to outpatient care and physician 
concern of ART resistance due to non adherence and incarceration [52, 55-57]. 
New strategies to better understand drug use and barriers to care are necessary for 
PWIDs to not only remain adherent to their ART regimens, but engaged in care 
overall.  
Assessment of illicit drug use 
Reliance on self-reported behaviors by drug users is common in epidemiologic 
studies. In the field, self-reports are often the only feasible method for capturing 
drug use and its related behaviors. In cohort studies, illicit drug use is often self-
reported over extended periods of recall (e.g., 6 to 12 months) [4, 54, 58]. There 
are several methods for self-reporting drug use including face-to-face interviews 
as well as audio-computer assisted self-interviews (ACASI) [59, 60].  
Face-to-face interviews, although fairly cheap, do increase the likelihood of social 
desirability bias and individuals tend to underestimate drug use. Social desirability 
bias is a reporting bias that arises when individuals under report specific behaviors 
or actions because they believe they are sensitive and not socially acceptable [61]. 
ACASI methods were created to address this issue and decrease social desirability 
bias by allowing greater respondent privacy. When using ACASI, questions are 
administered audibly and in text on a computer screen in a private room without 
the direct participation of a study interviewer [62]. Historically, ACASI has 
resulted in greater disclosure of sensitive information such as, illicit drug use, age 
of onset of injecting, injecting practices, rates of sharing syringes and risky sexual 
behaviors (e.g. condom usage and frequency of unprotected sex) [62-64]. 
Additionally, the use of ACASI methods tend to reduce the amount of missing 
data because it is thought that the simultaneous use of visual and verbal cues 
(computer screens and recorded speakers) encourages participants to pay greater 
attention to the questions [63].   
 
ACASI-based methods do share the same limitations as face-to-face interviews. 
Despite the ability to capture information on sensitive information, recall bias 
remains a problem. Questions concerning duration, frequency and amount of drug 
use are difficult to remember when assessed every 6-months (the traditional study 
visit interval of epidemiologic studies). Additionally, both under and over 
reporting of drug use behaviors occurs because of long periods of time between 
study visits. 
 
Biological samples of hair, urine, sweat or blood assess the biochemical markers 
of drug use, are considered more accurate than self-report and the recognized gold 
standard in estimating illicit drug use [65]. The utility of these methods lies in 
their ability to detect the length of time drugs have been in the body (depending on 
the biological specimen) and are widely used in drug testing and treatment 
settings.  
Urine toxicology testing has been the most commonly practiced method of drug 
screening in the workplace, criminal justice system and drug treatment settings 
over the past two decades because of the wide array of drug types easily detected 
by urinalysis [66]. Urinalysis has good sensitivity and specificity for the detection 
of recent drug use (e.g., detection of opiate or cocaine use within the past 24-48 
hours [67]).  However, to determine an individual’s use pattern, urine collection 
would be required every 2-3 days. Additional limitations of urinalysis include the 
difficulty of obtaining a spontaneous sample, the invasive nature of testing and the 
short detection window. This short detection window is problematic when there is 
less frequent contact with participants, as is often the case with epidemiologic 
studies and outpatient treatment settings [68]. 
Sweat patches are another method for detecting drugs in the body. They are a 
convenient, less invasive method with a longer window of detection for assessing 
drug use. Similar to urinalysis, drugs detected in sweat include the ‘parent drugs’ 
(the same chemical compound that was taken by the drug user) and drug 
metabolites (breakdown products of the parent drug) and are excreted by sweat 
glands. Unlike urinalysis, which reports drug use as positive or negative based on 
the presence of metabolites at a standard quantity cut off of 300 ng/ml, sweat 
patches are able to describe drug use by quantifying the amount of metabolites in 
the sweat over the duration of wear at 10 ng/ml [67]. The utility of the patch is that 
it can be worn for up to 10 days and is able to capture any drug use that occurred 
during the period of wear as well as the 24 hours prior to patch application. 
However, sweat patches do not capture as many drug types as urinalysis. The 
patch is designed to be flexible, waterproof, and safe from environmental 
contaminates [69] but can be easily removed. In fact, once the patch comes off the 
skin, it cannot be put back on the skin and resume drug use capture.  Despite being 
the gold standard for the assessment of drug use, biological samples remain 
difficult to collect in the field, can be cost prohibitive and require substantial 
participant engagement (e.g. weekly returns to treatment facility for urine test or 
patch removal).  
Reliability and validity of self-reported and biological methods of drug use 
assessment 
The reliability of a test refers to the extent that it has overall consistency. Parallel 
forms of reliability refer to whether different versions of an assessment tool 
produce similar results under consistent conditions (i.e., repeatability).  For 
example, do self-reports of drug use match the reports of biologic sample or 
ACASI reports? The validity of a measurement tool describes the degree to which 
it is able to scientifically answer the question it is intended to answer (e.g., does 
urinalysis actually capture recent drug use?). Concurrent validity is a type of 
validity that is demonstrated when a test correlates well with a measure that has 
been previously validated. These measurement properties are independent of one 
another; a measurement may be valid but not reliable or reliable but not valid. 
With respect to assessing drug use, biologic samples (including sweat patch and 
urinalysis) and self-reports via face-face-face interview or ACASI have been 
previously described as valid and reliable measures [70, 71]; however, mixed 
results have been described when these methods are compared to one another and 
vary depending on the drug being investigated.  
Studies examining the validity and reliability of sweat patch methods have 
examined the correlation between patch and urine results as well as a participant’s 
self-reported frequency of use. Prior validation studies using sweat patches and 
known doses of cocaine and heroin describe the patch sensitivity and specificity 
for cocaine as 86% and 97% [72] and 87% and 93% for heroin [73]. A 10-week 
outpatient clinical trial in which participants wore sweat patches, provided urine 
samples and self-reports of cocaine use thrice weekly, demonstrated the 
concurrent validity of urine and sweat patches to be reasonable (correlation: 0.76, 
p<0.001), but the correlation between self-report and the patches to be lower 
(correlation: 0.40, p<0.05) [67]. In this study, the authors used urinalysis as the 
previously validated measure of assessing drug use.  A separate outpatient study 
examining the utility of sweat testing for monitoring drug use found the level of 
agreement between positive sweat test results and positive urine results to be 33% 
for heroin and 92% for cocaine. When compared to self-reports, sweat patches 
were positive in 32% of cases reporting recent heroin use and 91% of cases 
reporting recent cocaine use. Comparisons of urine toxicology screens and patient 
self-reports showed that self-reports matched urine results in 88% of cases of 
heroin use and 78% of cases of cocaine use [68]. The analysis clearly 
demonstrates that the parallel reliability of these methods is not only different 
depending on which methods are being tested but the reliability also differs 
according to the drug being tested.  
The ability to accurately assess illicit drug use remains difficult in epidemiologic 
studies despite the many methods available. Yet, self-reported drug use remains 
the most widely employed method of assessing drug use. This is because studies 
continue to demonstrate drug users’ ability to provide sufficient, reliable, and valid 
descriptions of their drug use and its context, whereas biological samples only 
assess biological markers of drug use itself [71]. 
Mobile Health (mHealth) 
The use of mobile phones for communication and access to information via the 
Internet has become nearly ubiquitous in both low- and high-income countries. At 
the end of 2013, the number of active mobile phone subscriptions was estimated at 
6.8 billion worldwide, or approximately 96 subscriptions for every 100 inhabitants 
of the world [74]. As of early 2014, cell phone ownership among adults in the 
United States exceeded 90% and 58% had a smart phone [75] . In the foreseeable 
future, the majority of the world’s population will have access to the Internet via a 
mobile device. With this expanded accessibility of increasingly powerful handheld 
devices has come recognition of potential applications for improving health and 
health care [76]. 
mHealth is defined by the Global mHealth Alliance as the practice of medicine 
and public health through the usage of mobile devices. Mobile devices include 
Portable Digital Assistants (PDAs), mobile phones or tablet computers for data 
collection, health services, and treatment support and information dissemination. 
The promise of mobile health technologies for strengthening health care delivery 
in resource-limited settings has been acknowledged by the United Nations Joint 
Programme on HIV/AIDS (UNAIDS) in development of its strategic plan [77]. 
mHealth is currently being used for health education and awareness, remote data 
collection and monitoring, communication and training for healthcare workers, 
disease and epidemic outbreak tracking and diagnostic and treatment support [78]. 
Use of mHealth in Research Settings 
Researchers and patients have begun to use mHealth to explore the potential for 
mobile technologies to improve health outcomes and lower costs by increasing 
patient engagement, improving provider quality, and optimizing efficiency in 
health care [79]. The rise of mHealth research began with a focus on text 
messaging. Text messaging has been effectively utilized to provide decision 
support to frontline health workers, to remind patients of appointments, and 
improve attendance at clinic appointments [80-83]. It has also been extensively 
used for the management of HIV treatment and care as well as for weight 
management, cognitive behavioral therapies, sexual health, and the control of 
diabetes [84-87].  
Prior to text messaging, behavioral interventions to promote adherence to 
antiretroviral therapy among HIV infected individuals included the use of alarm 
devices or counseling sessions with the hopes of creating individualized 
interventions to increase adherence. One study, a four arm randomized clinical 
trial (RCT) in Kenya, examined the differences in counseling alone, a pocket 
electronic pill reminder, counseling plus the pill reminder or neither on time to 
virologic suppression and percent adherence to ART. Participants were followed 
for 18 months after ART initiation; those receiving counseling were less likely to 
have monthly adherence <80% and there was no impact of alarm use on poor 
adherence [88]. 
Text messaging has been used for ART dose reminder messages in several settings 
to improve adherence [9-11]. Two randomized controlled trials (RCTs) of 
mHealth in Sub-Saharan Africa have demonstrated benefit of weekly text 
messages for improving adherence [7, 8] and rates of viral suppression [8]. A 
meta-analysis of these RCT studies in Kenya demonstrated that any weekly text-
messaging (long or short) was associated with a lower risk of non-adherence at 48-
52 weeks (RR 0.78, 95% CI 0.68-0.89) [12].  
More recently, sophisticated mobile devices (e.g., accelerometers to measure 
physical activity and sensors to measure heart rate, blood pressure, or other 
biological processes) have arisen from the built-in computer chips and geographic 
sensing power of newer mobile technologies [79]. These systems have enabled 
health researchers to define profiles of behaviors and risk exposures with more 
granularity in real-time. These noninvasive devices and sensors allow physiology 
to be monitored continuously with little to no engagement by the individual. 
Combining these technologies with traditional text messaging that inquire about 
behaviors, mood or location offer new epidemiological methods for assessing 
daily behavioral cues and activities.  
Despite the increasing availability and enthusiasm for mHealth tools, evidence-
based research to understand substance-using populations remains limited. Early 
use of mHealth methods among substance using populations showed that in 
substance abuse treatment settings, active cocaine and heroin users can reliably 
report mood and drug use triggers using electronic handheld diaries [89, 90].   
Ecological Momentary Assessment  
Traditional data collection methods of cohort studies require participants to attend 
study sites every 6 months (although this time interval can vary) to answer 
questionnaires/surveys concerning events in those past 6 months. At best, data is 
obtained twice a year if a participant is retained in the study.  
Ecological momentary assessment (EMA) methods utilize smart phones or hand 
held devices to collect data concerning study participants; these technologies may 
be the participant’s personal phone or provided by the study. Typically in EMA 
studies, momentary assessments are ascertained when the provider or investigator 
sends electronic prompts to participants for immediate response randomly 
throughout the day (typically waking hours 7am-10pm, at which point the device 
can be charged and/or turned off for the day), known as the random-prompt 
responses. Additionally, participants are required to self-cue and self-report 
through the mobile device when an event occurs, known as event-contingent 
responses. The random prompts enable assessment of the base rates of exposure to 
possible relapse precipitants such as cues and stressors [91]. Data collected 
through random prompts also enables a truly prospective approach to the question 
of what events preceded a specific event episode. The event-driven data provide 
near real time self-report of such episodes.  
The hand held-devices are sometimes also equipped with global positioning 
systems (GPS), which allow for continual data collection of the participants 
location at the time of the reported event. The two-way communication is how 
EMA allows for real-time data collection on any activity or mood. Utilizing EMA 
methods of real-time data collection, sociodemographic, behavioral and situational 
factors can be more precisely measured. 
Ecological Momentary Assessment and substance abuse 
EMA methods have been used in behavioral research concerning smoking 
cessation, weight loss and recently, cravings of heroin and cocaine [89, 92-94]. 
Epstein and Preston were some of the early adopters in using EMA methods to 
study drug-using populations in the U.S. An initial study utilizing EMA with 
Personal Digital Assistants (PDAs), examined how smoking was related to other 
drug use and craving during daily life. It was found that smoking frequency 
increased with increased reports of tobacco, cocaine and heroin cravings captured 
through the random-prompts, while smoking and tobacco cravings were reduced 
during periods of urine verified abstinence from cocaine [92].  
In a separate study, data were collected among methadone-maintained outpatient 
participants during urine-verified periods of use and abstinence to further 
understand patterns of daily illicit drug use. Periods of cocaine use were associated 
with idle and solitary afternoons, and also associated with a greater likelihood of 
early-morning or late-evening work. Additionally, several measures of negative 
mood increased during abstinence [89]. The aim of this study was to examine 
distinct patterns of mood and behavior to inform treatment interventions aimed at 
changing daily activities.  
 
To examine stress’s role on drug use, Preston et al. used EMA data collected from 
methadone-maintained cocaine and heroin users who provided ratings of stress 
which were compared to those of craving and mood in the hours prior to drug use. 
Stress was shown to have a significantly positive relationship with current 
cravings of cocaine and heroin and was greater in entries in which participants 
also reported past-hour exposure to negative-mood triggers of sadness and 
boredom [95].  
 
These studies were novel as they used EMA to examine the “situatedness” of drug 
use, the context in which drug use occurred and how mood affected drug use. The 
real-time nature of data collection using EMA also provides for the examination of 
the main exposures that precede events of interest. Utilizing the same population 
of methadone-maintained cocaine and heroin outpatients, Epstein et al examined 
changes in reports of mood and exposure during the 5 hours preceding each self-
reported episode of drug use or craving [90]. Cocaine use was statistically 
significantly associated with increases in participant reports of “seeing the drug”, 
being “tempted out of the blue” and “wanting to see what would happen if I used”, 
whereas heroin craving was statistically significantly associated with increased 
reports of feeling sad or angry. Neither cocaine craving nor heroin use showed 
associations with the triggers assessed [90].  
 
Each of these studies demonstrated the ability of polydrug using individuals’ 
ability to provide behavioral data during their daily life, the feasibility of using 
hand-held devices as well as the ability to consistently respond to questions 
concerning their drug use. It is for these reasons that ecological momentary 
assessment is regarded as a more precise measure of experienced well-being [96]. 
 
Goals of the dissertation 
 
Current methods for assessing drug use rely heavily on drug type and manner of 
use often over prolonged intervals of follow-up. These methods miss varying 
periods of intense or intermittent use and further fail to capture the proximate 
context of an individual’s drug using experience. The goal of this dissertation was 
to examine the drug-using environment of chronic illicit drug users in their 
natural settings (rather than a clinical or drug treatment population) using an 
interactive mobile health method. Using ecological momentary assessment data, 
this dissertation aimed to assess the concordance of assessing drug use via EMA 
methods to biological and ACASI methods, describe drug-using patterns and their 
association with engagement in care and assess the situational and psychosocial 
triggers of drug use.   
This dissertation examined the drug using and craving behaviors of participants 
from The Exposure Assessment in Current Time (EXACT) Study. EXACT 
participants were recruited from The AIDS linked to the Intravenous Experience 
(ALIVE), an on-going, community-recruited, observational cohort study of 
persons with a history of injecting drugs in Baltimore [97]. The ALIVE cohort is 
community- rather than clinic-based, thereby avoiding selection bias toward 
persons seeking or accessing care [97, 98]. Details of the EXACT study have been 
previously described [99], and included four successive trials conducted from 
November 2008 through May 2013. Each trial was planned to follow 30 
participants each for 30 days. Overall, EXACT participants lost one device for 
every 190 days of observation and answered 78% of random-prompts, a response 
rate comparable to other EMA studies performed using similar technologies in 
varied settings [90, 93] 
Ecological momentary assessment methods were used to collect data on 
participant’s drug using behaviors. This method employs hand-held devices 
(Personal digital assistants or mobile phones) that delivered four prompts to 
complete surveys at random times daily between 8am and 9pm (known as random-
prompt entries), and one end-of-day (around 9 pm) survey for 30 days of 
observation. Participants were also asked to self-initiate a survey and self-report 
each time they either craved (but refrained from using) or used heroin or cocaine 
(or both) in any manner (smoked, snorted or injected); these responses represent 
event-contingent entries. Heroin only and cocaine only reports incorporated all 
reports of heroin or cocaine use (including those jointly with another drug).   
For each event, participants answered questions concerning their drug use, current 
mood, social, physical and activity environment, using survey instruments adapted 
from previous EMA studies [89, 90, 95, 100, 101].   Participants had 30 minutes to 
complete an event-contingent survey to ensure responses were recorded in real-
time. PharmCheck® Drugs of Abuse Patches (PharmChem Inc.) were collected 
weekly for the assessment of heroin or cocaine use and at the conclusion of each 
study week, participants returned to the study site to answer an ACASI that 
included questions concerning activities, behavior and drug use frequency during 




Accordingly, the specific aims of this dissertation are: 
AIM 1:  To evaluate the concordance of ecological momentary assessment (EMA) 
methods of drug use to previously validated biological and audio-computer 
assisted self-interview (ACASI) methods among persons who inject drugs  
(PWID).  
The assessment of illicit drug use via EMA methods has not been previously 
examined. To do this, EMA methods must be examined in relation to other already 
known valid and reliable assessment methods including biological sweat samples 
and self-reports via ACASI interviews.  (Chapter 2) 
AIM 2: To develop ‘drug using profiles’ collected through Ecological Momentary 
Assessment (EMA) methods and determine whether these risk profiles are 
associated with engagement in care.  
Unique characterization of drug use at the individual level will enable providers 
to have a better understanding of a patient’s expectant success of appropriately 
engaging in care. (Chapter 3) 
AIM 3: To examine the real-time social, physical, environmental and psychosocial 
cues of using versus craving drugs among a sample of drug users utilizing 
Ecological Momentary Assessment (EMA) methods.  
Improving drug treatment outcomes and preventing HIV infection among this 
high-risk population requires preventing drug relapse. Using ecological 
momentary assessment methods, we hope to improve our understanding of the 
proximate environmental factors of drug use relative to drug craving. (Chapter 4) 
 
Figure 1.1 describes the time intervals of drug use assessments for these analyses. 
Weekly, daily and real-time intervals for the assessment of drug use were 
examined through the use of EMA, ACASI and sweat patch methodologies. The 
use of real-time mHealth methods allows for the assessment of drug use in more 
refined time intervals and will provide a better understand of varying periods of 
intense and intermittent drug use and capture the proximate context of the drug 
using experience.  
 
Overall, this systematic characterization of drug use will allow for more accurate 
prediction of the triggers of drug use or relapse and can inform development of 





The Information-Motivation-Behavior (IMB) model of adherence suggests 
adherence information, motivation and behavioral skills interact to determine 
engagement in care and adherence behaviors [102]. Informed patients include 
those who are aware they are in need of care as well as the obstacles and barriers 
to receiving care, including the environments that promote drug craving versus 
drug use. Motivated individuals include those who have positive attitudes 
concerning preventing drug relapse and engaging in care, have adequate social 
support and understand the consequences of non-adherence to care. If an 
individual is informed and motivated, according to the IMB theory, they will enact 
adherence related “behavioral skills” such as self-cueing and self-initiation of 
reducing risky drug-using behaviors and engaging in care, which will result in 
adherence-related behaviors [102].  
 
It is these behaviors that result in favorable drug treatment outcomes, reductions in 
drug relapse and positive HIV treatment outcomes such as viral load suppression. 
The IMB theoretical framework suggests well-informed, well-motivated patients 
who possess adequate skills for enacting complex patterns of adherence-related 
behaviors will be less likely to relapse and reduce risky behaviors over time. Yet, 
even patients who are well informed may or may not be capable of self-motivation 
or lack the correct behavior skills to comply with treatment due to life 
circumstances, such as injecting drugs, co-morbidities such as depression, unstable 
housing or limited access to care.   
 
The proposed conceptual framework (Figure 1.2) contextualizes the IMB model 
through consideration of sociodemographics, drug use duration, manner and 
amount used per day as well as whom the individual was with while using drugs: 
friend, acquaintance, family member, a stranger, a spouse, and a child, alone, 
someone currently using drugs (Social Environment), what activity was the 
participant engaged in when they decided to use: socializing, sleeping, eating, 
shopping, planning/thinking, drinking alcohol, using tobacco, offered drugs, saw 
or were with someone using drugs, saw drug paraphernalia, handling $10 in cash 
(Activity Environment), where were they when they decided to use: home, 
another’s home, car, bus or train, outdoors, church, job/working, restaurant, 
abandoned space (Physical Environment) and what was the participant’s mood or 
motivation when using: happy, stressed, tired, relaxed, bored, irritated 
(Psychosocial Environment (Figure 1.2). “Situatedness” in this model allows for 
the recognition that patient behavior is occurring within a specific cultural, 
organizational, and structural environment and that outcomes are fundamentally 
linked to situational and individual factors that may affect drug-using behaviors 
[103].  
 
We hypothesize that by including social, activity, psychosocial and physical 
environmental factors collected in real-time into the characterization of drug use, 
we can better understand drug use and drug craving and the subsequent outcomes 
associated with these events among chronic drug users.  Real-time mHealth 
methods, such as ecological momentary assessment, will allow for a rich 
characterization of the drug-using environment beyond the examination of 
adherence behaviors alone.  We also hope to provide evidence for the use of EMA 
methods to efficiently an effectively collect high quality epidemiological data 
among a traditionally known hard to reach population. 
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Figure 1.2: Conceptual frame work of proposed work
Chapter 2: 
Ecological momentary assessment of illicit drug use compared 
to biological and self-reported methods 
Abstract 
Objective: We examined the concordance of ecological momentary assessment 
(EMA) methods of drug use to previously validated biological and audio-computer 
assisted self-interview (ACASI) methods. 
Methodology: The Exposure Assessment in Current Time (EXACT) study 
utilized EMA methods to assess drug use in real-time in participants’ natural 
environments. Participants were provided mobile devices and asked to self-report 
every time they used heroin or cocaine over a 4-week period. At the end of each 
week, weekly PharmCheck® sweat patch samples were collected for measurement 
of illicit substances. Similarly, participants answered an ACASI-based 
questionnaire to report activities, behavior and drug using events during the prior 
week.  Reports of cocaine and heroin use captured through EMA methods were 
compared to weekly biological or self-report measures through percent agreement 
and kappa statistics. Correlates of discordance were obtained from logistic 
regression models. 
Results: 109 participants were a median of 48.5 years old, 90% African 
American, 52% male and 59% HIV-infected. In analysis of 424 person-weeks of 
observation, 212 (50%) cocaine and 103 (25%) heroin sweat patches, 192 (45%) 
and 161 (38%) ACASI surveys and 163 (38%) and 145 (45%) EMA reports of any 
cocaine and heroin use were captured over follow-up. The percent agreement 
between EMA and sweat patch methods was 70% for cocaine use and 72% for 
heroin use, while the percent agreement between EMA and ACASI methods was 
77% for cocaine and 79% for heroin use. Misreporting of drug use by EMA 
methods compared to sweat patch and ACASI methods were different by illicit 
drug type and reflected both the limitations of the assessment methods as well as 
our sample of more intense high-risk drug users.  
 
Conclusions:  Our work demonstrates moderate agreement of EMA methods to 
biological and standard self-report methods in capturing illicit drug use. 
Limitations occur with each method and accuracy may differ by type of illicit 
drugs used.  
  
Introduction 
The detection of biochemical markers of illicit drugs in biological samples of hair, 
urine, sweat or blood is considered the gold standard for assessing illicit drug use 
and is widely used in drug treatment and employment drug testing settings [1]. 
The utility of these methods lies in their ability to detect metabolites of illicit drugs 
used within a specific window of time that varies depending on the biological 
specimen. Despite being the gold standard for the assessment of drug use, 
biological samples are often difficult to collect in the field, may be cost prohibitive 
and can require greater participant engagement (e.g., frequent urine screens at a 
treatment facility). Additionally, biologic samples typically only assess whether an 
individual has previously used drugs rather than quantifying how much of the drug 
was consumed [2, 3].  Whereas fluid samples tend to assess drug use over 
relatively short windows of time and hair and nail clippings can detect longer 
periods of drug use, these approaches fail to detect patterns of drug use, such as 
binging or intermittent use.  
In epidemiologic studies, the most feasible method of assessing illicit drug use is 
self-report, which often collects data over extended periods of recall (e.g., 6 to 12 
months or longer) [4-7]. The benefit of self-report via survey methodology 
includes the ease of use, convenience and low cost as well as allowing for further 
assessment of risk factors and correlates of drug use (e.g., frequency of use, needle 
sharing practices or sexual risk-taking practices). However, whether assessed via 
study interviewer or audio-computer assisted self-interview (ACASI), these 
methods may involve substantial recall, response and social desirability biases [8, 
9]. Additionally, these methods require participants to return to the clinic or study 
site at regular intervals, which not only requires participants to have reliable 
transportation options but also disrupts their daily routines. Despite these potential 
issues, assessment of illicit drug use through self-report has been shown to be a 
valid and reliable measure of drug use [2, 10-12].    
 
Both self-report and biological testing methods of capturing drug use lack the 
ability to assess real-time drug use, will miss varying periods of intense or 
intermittent drug use, and cannot ascertain the proximate context of an 
individual’s drug using experience [13]. Ecological momentary assessment (EMA) 
methods collect participant-level data in real time over notably shorter time 
intervals 
 
Mobile health (mHealth) strategies that employ mobile devices (e.g., smartphones 
or other hand-held devices) can utilize EMA methods for remote data collection 
and monitoring as well as health education and intervention mHealth methods 
hold promise for improving health outcomes, healthcare services and public health 
research [14]. EMA methods have been utilized in smoking cession studies [15-
21] and among methadone-maintained outpatient drug users [22-26] but have yet 
to be validated as reliable methods for assessing drug use. By capturing drug-using 
events in real-time, outside of the study clinic and in participant’s natural settings, 
a more robust, vibrant and comprehensible understanding of drug use can be 
generated beyond periodic biological detection or infrequent self-reports of drug 
use.  
 
Prior studies have examined concordance between the assessment of drug use by 
biological measures and self-report [27-29]. The aim of the current study was to 
investigate the concordance of assessing drug use via EMA methods compared to 
biological and ACASI methods. We additionally identified correlates of 
discordance and examined the feasibility, strengths, and weaknesses of these 
methods in assessing drug use among a community sample of drug users in 
Baltimore, MD.  
 
Methods 
EXACT study participants 
Exposure Assessment in Current Time (EXACT) study participants were recruited 
from the AIDS Linked to the IntraVenous Experience (ALIVE) study, an on-
going, community-recruited, observational cohort of persons with a history of 
injecting drugs in Baltimore, MD [7]. The ALIVE cohort is community- rather 
than clinic-based, thereby avoiding selection bias toward persons seeking or 
accessing care. Details of the EXACT study have been previously described [30], 
and included four successive trials conducted from November 2008 through May 
2013. Each trial was planned to follow 30 participants each for 30 days. The Johns 
Hopkins School of Public Health Institutional Review Board approved the study 
protocol. All participants provided written informed consent. Participants were 
informed that involvement (or non-involvement) in EXACT would in no way 
affect their participation in ALIVE. 
 
Eligibility criteria for the EXACT study included current enrollment in ALIVE 
and the ability to understand and follow directions on a personal digital assistant 
(PDA) or mobile phone.  Individuals were excluded if they had any medical 
conditions that would prevent them from operating the hand-held device (e.g., 
vision or hearing impairment) or failed to attend the screening appointment where 
they were trained on device use.  
 
In each trial, the specific inclusion criteria regarding drug use and HIV status were 
varied slightly to ensure a diverse overall sample; both injection and non-injection 
drug users were included.  In Trial 1, selection was made to balance the numbers 
of participants that reported heroin or cocaine use within the past month (defined 
as recent drug use) with those that were not currently using drugs. In Trial 2, all 
participants reported heroin or cocaine use within the prior three months. While 
HIV status was not a recruitment criterion in the first two trials, Trial 3 included 
only HIV-infected participants with recent heroin and cocaine use. These same 
criteria were also used in Trial 4, but the data collection was transitioned from a 
PDA to a smartphone platform [30].  
For Trials 1-3, participants were provided personal digital assistants (PDA, Palm 
Z22, Palm, Inc., Sunnyvale, CA, USA) running applications developed using 
Satellite Forms software (http://patches.satelliteforms.net/). All PDA programs 
were disabled except for study-required applications. In Trial 4, participants were 
provided an Android Smartphone (Motorola Droid X2), running an application 
developed using the Electronic Mobile Open-source Comprehensive Health 
Application (eMOCHA) platform, created at Johns Hopkins School of Medicine.  
EMA Data Collection 
For 30 days of observation, participants were asked to self-initiate a survey on 
their hand-held device to self-report each time they either used heroin or cocaine 
(or both) in any manner (smoked, snorted or injected). For each event, participants 
answered questions concerning their drug use, current mood, social, physical and 
activity environment, using survey instruments adapted from previous EMA 
studies [22-26].   To ensure responses were recorded in real-time, participants 
were required to indicate that dug use had occurred within 30 minutes of 
completing this survey. The device also delivered an end-of-day (around 9 pm) 
survey that asked if there was any drug use that was not reported earlier in the day.  
 
Sweat Patches 
PharmCheck® Drugs of Abuse Patches (PharmChem Inc.) were collected weekly 
for the assessment of heroin or cocaine use. These patches can detect traces of 
cocaine or heroin secreted in sweat during the period it is worn. Additionally, 
sweat patches reduce the number of participant visits to the study site thereby 
reducing any biases associated with missed visits due to drug use. Drugs captured 
via PharmCheck® Sweat Patches represent ‘parent’ drugs (same chemical 
compound that was taken by the drug user) and drug metabolites (breakdown 
products of the parent drug) excreted through sweat. The patch can be worn up to 
10 days and is able to capture any drug use that occurred during the period of wear 
as well as 24 hours prior to patch application [31].  To ensure the patch stayed in 
place, an additional overlay made of the same adhesive material was worn atop the 
sweat patch. Once removed, patches were sent to a commercial laboratory for drug 
evaluation (Clinical Reference Laboratory, Lenexa, KS). Specimens were initially 
screened using an enzyme immunoassay technique (ELISA) with positive patches 
undergoing confirmation using liquid chromatography/mass spectrometry/mass 
spectrometry (LC/MS/MS)[31].  
 
Cocaine predominates in sweat after cocaine use, however the most common 
metabolite of cocaine is benzoglecgonine (BZ). A positive sweat patch result for 
cocaine use is confirmed by the presence of both BZ and cocaine at or above the 
limit of detection of 10ng/mg.  Topical analgesics, such as lidocaine or novacain, 
contain BZ and are used in various surgical procedures, however cocaine is 
structurally unique and does not resemble any of these products [31]. 
 
Opiate metabolites detectable by sweat patch include heroin, 6-
monoacetylmorphine (6-MAM), codeine and morphine. The presence of 6-MAM 
can only come from the use of heroin. A positive sweat patch for heroin includes 
the presence of the parent drug (heroin) and morphine above the limit of detection 
of 10ng/ml, 6-MAM and morphine above the limit of detection of 10ng/ml or 6-
MAM alone above the limit of detection of 10ng/ml. The presence of morphine 
alone may be due to the use of other opiate containing legal medications (e.g. 
oxycodone, hydrocodone) or the consumption of certain foods, like poppy seeds. 
Therefore, the presence of morphine alone does not indicate a positive sweat patch 
for heroin [31]. 
 
Self-report by ACASI 
At the conclusion of each study week, participants returned to the study site to 
answer an ACASI that included questions concerning activities, behavior and drug 
use frequency during the prior week. Additionally, baseline participant 
characteristics were obtained from ACASI completed at enrollment into EXACT 
and/or from the prior ALIVE study visit. In addition to sociodemographic 
variables (e.g., age, sex, race, education, marital status, employment, income, 
homelessness and health insurance status), baseline data collection included self-
reported alcohol, tobacco and illicit drug use, an index of drug abuse [Drug Abuse 
Screening Test (DAST)] and depressive symptoms [Center for Epidemiologic 
Studies- Depression Scale (CES-D)] in the prior six-months [32]. Clinical 
characteristics (e.g. HIV/antiretroviral therapy status, CD4 T-cell count, HIV RNA 




To ensure accurate comparisons between each method of capturing drug use, all 
analyses were assessed by week (this was necessary as the ACASI and sweat 
patch data were only collected weekly).  The day in which the sweat patch was 
placed on the participants arm and in which the hand-held device was provided 
represented the start of the study week 1. Seven days later, when the ACASI was 
completed, marked the end of the week. At this time, the sweat patch was removed 
and replaced with a new patch and repeated for all 4 weeks of the study.  Drug use 
reported by ACASI and sweat patch indicated use or no use within the prior week.  
 
Real-time heroin or cocaine use, reported via the EMA event-contingent entries or 
the end-of-day survey were summed by day and week for each participant. For 
analysis, an individual was considered to have used drugs if at least one report of 
drug use (heroin or cocaine use by any manner) was reported in real-time within a 
given study week.  Heroin only and cocaine only reports incorporated all reports 
of heroin or cocaine use (including those jointly with the other drug).   
 
Because the sweat patch was able to capture drug use that included the 24hrs prior 
to adhesion, the EMA week was offset by 1 day to ensure concurrent periods of 
time were evaluated when comparing the methods.  There was no adjustment for 
time for comparisons between EMA and ACASI-assessed drug use.  
 
To examine the concordance of drug use reported by EMA to sweat patch or to 
ACASI methods, percent agreement and kappa statistics were calculated.  The 
kappa statistic is a measure of the level of agreement (also known as inter-rater 
reliability) that takes into account the agreement occurring by chance. Kappa 
values of less than 0.2 are considered poor; 0.21-0.40 fair; 0.41-0.60 moderate; 
0.61-0.80 good; and 0.81-1.00 very good [33]. 
 
If the number of EMA events in any week was greater than the number of ACASI 
or sweat patch responses it was considered EMA over-reporting, while EMA 
under-reporting was determined if the number of EMA reports were fewer than 
those reported by sweat patch or ACASI. To determine correlates of discordance 
between methods of assessing drug use, logistic regression models with 
generalized estimating equations (GEE) were examined. GEE methods adjusted 
for the correlation of repeated measures within each subject over the 4 weeks of 
follow-up. Variables selected for the final multivariable models were chosen 
through step-wise logistic regression with inclusion of significant variables (p-
value <0.1) from the univariate analyses. Analyses were performed using STATA 
Statistical Software: Release 12 (College Station, TX: StataCorp LP).  
 
Results 
Among 109 EXACT participants contributing 424 weeks of observation (Table 
2.1), the median age was 48.5 years (interquartile range (IQR) 43-53 years), 90% 
were African American, 52% were male and 59% were HIV infected. In the six-
months prior to baseline assessment, 23% of participants reported recent 
methadone treatment and 83% reported smoking cigarettes. 
 
Comparison of methods to capture illicit drug use 
 
Out of a possible 436 weeks of follow-up, 12 weeks did not have evaluable EMA 
assessments of drug use (weeks where no drug use was reported via EMA), 
resulting in 424 weeks (97%) of observable data. Over 424 weeks, 396 (93%) 
sweat patches were returned and 410 (97%) ACASI surveys were completed (14 
were incomplete). Twenty-two individuals were unable to return 29 sweat patches 
(7%) because the patch was damaged or removed prematurely. 12 individuals did 
not complete 14 (3%) weekly ACASI surveys. Total weeks of drug use obtained 
from sweat patch, ACASI, and EMA methods are described in Figure 2.1. Reports 
of drug use by EMA represent any report in a week and not the number of 
individuals or the total amount of uses in a week.  
Over study follow-up, 212 (50%, green bars) cocaine positive sweat patches, 192 
(45%, blue bars) ACASI surveys and 163 (38%, orange bars) weeks of EMA 
reports of any cocaine use were captured over follow-up. For heroin use, 103 
sweat patches (25%), 161(38%) ACASI surveys and 145 (34%) weeks of EMA 
reports were captured over follow-up. Seventy-seven sweat patches (18%), 117 
(28%) ACASI surveys and 96 (23%) weeks of EMA reports captured both cocaine 
and heroin use. The proportion of sweat patches with heroin and cocaine detected 
remained stable by study week.  
For cocaine use, the overall percent agreement between EMA and sweat patch 
methods was 70% (Figure 2.1a, blue bars) (Table 2.2) and for EMA and ACASI 
methods was 77% (Figure 2.1a, green bars). For heroin use, the percent agreement 
between EMA and sweat patch methods (Figure 2.1b, orange bars) was 72% and 
for EMA and ACASI methods (Figure 2.1b, yellow bars) was 79%. With heroin or 
cocaine use, the percent agreement was slightly higher between the EMA and 
ACASI methods compared to EMA and sweat patch assessments.  
Percent agreement does not take into consideration the agreement between two 
methods solely due to chance. The kappa statistic is a measure of inter-rater 
reliability that takes into account the agreement occurring by chance. The kappa 
statistics were slightly lower for comparisons of drug use between EMA and sweat 
patch methods than observed for EMA and ACASI methods. The kappa statistics 
for the comparison of EMA and sweat patch methods were in the moderate 
agreement range for both cocaine 0.51 (0.44-0.60) and heroin 0.48(0.38-0.57) use. 
The agreement in reports between EMA and ACASI methods for cocaine use was 
0.59 (0.51-0.67) and for heroin use was 0.61 (0.53-0.69), with the former 
representing moderate agreement and the latter representing good agreement. 
 
Misreporting of responses by EMA relative to sweat patch and ACASI methods 
were assessed for cocaine and heroin separately (Table 2.2).  Relative to sweat 
patch results, under-reporting of drug use by EMA methods was more likely for 
heroin than cocaine use (19% vs. 9%), but over-reporting by EMA methods was 
greater for cocaine than heroin use (21% vs. 8%). Misreporting was identified less 
commonly between EMA and ACASI methods. Compared to ACASI reports, 
under-reporting by EMA was infrequent and similar for cocaine and heroin use 
(8% vs. 9%). Over-reporting by EMA relative to ACASI was slightly greater for 
cocaine than heroin use (15% vs. 13%).  
 
 
Comparison of methods to quantify illicit drug use 
Variations in weekly self-reported drug use intensity by EMA and ACASI 
assessment methods are described in Figure 2.3. Among persons reporting any 
cocaine use during the week by the specified method, the median number of self-
reports of cocaine use captured by ACASI (Figure 2.3a, blue boxes) was 4 
(Interquartile Range [IQR] 2-6) and the median number of cocaine events captured 
by EMA (Figure 2.3b, red boxes) was 3 (IQR 1-5). Cocaine events reported via 
ACASI ranged from 1 to 50 in any week. The greatest number of cocaine use 
events assessed in any week via EMA was 24.  
 
Similarly, the median number of self-reported heroin use events assessed by 
ACASI (Figure 2.3b, green boxes) was 4 (IQR 2-7) while the median number 
captured by EMA (Figure 2.3b, orange boxes) was 2 (IQR 1-4).  The greatest 
number of heroin uses captured by ACASI in any one week was 64 while the 
greatest number of heroin uses in any week captured by EMA was 38. End of day 
reports did not substantially impact the daily amount of reported drug use nor did 
they substantially change the classification of drug use weeks by EMA (data not 
shown).    
 
Correlates of EMA misreporting 
We sought to identify sociodemographic, behavioral or clinical factors associated 
with over- or under-reporting of drug use by EMA. In multivariable analyses, 
relative to sweat patch results, there were no significant correlates of EMA over-
reporting of cocaine use (Table 2.3A). Under-reports of cocaine use by EMA were 
almost 2-fold less likely among females (Adjusted Odds Ratio [aOR] 0.47, 95% 
Confidence Interval [CI]: 0.23-0.98) and 80% less likely among individuals who 
reported injecting once per day or more at baseline (aOR 0.21, 95%CI: 0.05-0.87). 
Although only marginally significant, individuals under 50 years of age were 
found to be less likely to under-report cocaine use as well (aOR 0.51, 95% CI: 
0.25-1.07).  
EMA over-reports of heroin use relative to sweat patches were twice as likely if 
heroin was used (self-reported) at baseline (aOR 2.10, 95% CI: 1.0-4.56), but 
baseline heroin use was also the only factor significantly associated with EMA 
under-reporting of heroin use (aOR 5.56, 95% CI: 1.37-22.46).  Female gender 
also achieved marginal significance in being less likely to under-report heroin use 
via EMA methods (aOR 0.31, 95%CI: 0.08-1.10). 
Compared to ACASI methods (Table 2.3B), EMA over-reports of cocaine and 
heroin use were twice as likely if a participant reported sharing injection needles at 
baseline (aOR cocaine 2.79, 95% CI: 1.03-7.5; aOR heroin 2.96, 95% CI: 1.17-
7.51).  Under-reporting of cocaine use by EMA was marginally associated with 
being married and was 6-fold more likely if individuals reported having medical 
insurance at baseline (aOR 6.62, 95% I: 1.16-37.76). EMA over-reports of heroin 
use were positively associated with baseline heroin use (aOR 3.04, 95% CI: 1.33-
6.95) as well as over 4-fold more likely if the participant was HIV infected (aOR 
4.56, 95% CI: 1.80-11.58).  
Discussion 
This analysis demonstrated moderate to strong concordance and inter-rater 
reliability of reported drug use by EMA when compared to either biological 
measures of sweat patches or more conventional ACASI self-report methods. 
However, our data raised concerns regarding the use of sweat patches as a gold 
standard for drug use assessment due to the notably lower prevalence of heroin use 
defined by biological detection compared to the prevalence of heroin use we 
determined in this study based on self-reported methods and to the expected 
prevalence based on prior data in our ALIVE cohort [7, 34]. Even relative to 
imperfect gold standards, we provide evidence that researchers should be 
confident that EMA methods can accurately capture and characterize illicit drug 
use comparable to currently used methods.  Given the relative benefits of daily 
real-time assessments of drug use in terms of reductions in recall bias, social 
desirability bias, participant burden and follow-up time, EMA methods for 
assessing drug use may have broad applications in settings ranging from 
epidemiological studies to behavioral interventions.  
EMA Compared to Sweat Patch Assessment 
Biological samples serve as the gold standard for assessing drug use because they 
are able to capture the biochemical components of drug use as the body excretes 
them. Sweat patches are often used to detect longer-term drug use as the patch can 
be worn continuously for up to 10 days and can continuously capture drug 
metabolites as they break down in sweat until the patch is removed. The patch is 
designed to be flexible, waterproof and safe from environmental contaminates 
[35]. The patch can be easily removed, but once the patch comes off the skin, it 
cannot be put back on to resume drug use capture. Current applications of sweat 
patch testing include use in drug treatment for monitoring drug relapse and for 
determining the effectiveness of medical and psychological therapy [36, 37].  
Our results suggest moderate concordance between EMA and sweat patch 
methods for assessing drug use. Prior studies have shown substantial discordance 
between self-report of drug use and biochemical tests results across out-of-
treatment populations [38]. A 10-week outpatient clinical trial in which 
participants wore sweat patches, provided urine samples and self-reports of 
cocaine use thrice weekly, demonstrated the concurrent validity of urine and sweat 
patches to be reasonable (correlation: 0.76, p<0.001), but the correlation between 
self-report and the patches was lower (correlation: 0.40, p<0.05) [39]. A separate 
outpatient study examining the utility of sweat testing for monitoring drug use also 
found the level of agreement between positive sweat test results and positive urine 
results to be 33% for heroin and 92% for cocaine [37]. 
 
The results of our sweat patch analyses demonstrated a notably greater number of 
cocaine positive sweat patches compared to heroin positive sweat patches. This 
finding was unexpected as our prior analyses with this EXACT population 
demonstrated heroin to be the predominate drug of use over 30 days of follow-up 
[30]. Additionally, recent estimates indicate that Baltimore suffers from a far 
greater public health burden of heroin abuse compared to cocaine use [40] and this 
is mirrored in the participants of the ALIVE study [7, 34].  Upon consultation with 
PharmChek®, manufacturers of the sweat patches, it was suggested this difference 
may have been the result of our heroin using participants using such small 
amounts of heroin, that even after a week of wearing the patch, did not secrete 
enough heroin metabolites to be detected at the limit of detection of 10 ng/ml 
(Matthew Hartley, personal communication).   
 
A recent study using PharmChek® sweat patches examined the stability of 16 
drugs at ambient temperatures and reported the degradation of heroin with high 
individual variability although this effect was not observed with cocaine [41]. We 
stored our sweat patches at room temp in compliance with PharmChek® protocols 
but have no way of knowing if any of our patches that tested negative, or were 
below the limit of detection for heroin, were false negatives as a result of possible 
degradation. Importantly, despite sweat patches from each week of the study being 
sent in batch for testing when the participant completed the trial, we did not 
observe any temporal differences in heroin detection by study week. 
 
Although concerns have been raised that sweat patches may serve as a deterrent to 
drug use [31], there was no incentive in this study to modify behavior and our self-
reported drug use data indicate greater heroin use. To explain our findings, there 
would have to be a differential effect resulting in heroin misreporting relative to 
cocaine in response to sweat patch placement, which seems implausible.  Yet, 
despite these problems of relatively lower heroin detection via sweat patches, the 
inter-rater reliability of EMA methods compared to sweat patch analysis remained 
moderate for both heroin and cocaine use as evidenced by kappa statistics.   
 
EMA Compared to ACASI Assessment  
ACASI methods have now become the standard approach for collecting sensitive 
data in epidemiologic research studies. The use of ACASI has resulted in greater 
disclosure of sensitive behaviors such as drug and sexual risky behaviors [42-44], 
thereby reducing social desirability bias and improving accuracy of self-report.  
Although the best time interval for assessing drug use exposure remains unknown, 
several studies have found that reporting sensitive sexual behaviors can be 
accurately recalled for intervals of 1–3 months [45, 46]. Longer time frames may 
be more representative of a person's behavior patterns, but can be more difficult to 
recall. It is likely that participants asked to recall behaviors over longer time 
periods may rely on a strategy such as “guestimation” of the average number of 
days per week they have been with a specific partner or used drugs [47]. Despite 
the potential problems with accuracy of information collected over longer periods 
of time, ACASI assessments are rarely done in shorter intervals due to practical 
issues.  
In this analysis, the inter-rater reliability and concordance of EMA methods 
compared to ACASI methods for assessing drug use appear stronger for heroin use 
(kappa statistic for heroin use had good agreement, 0.61[0.53-0.69]) than for 
cocaine use. Both methods involve self-report in settings with increased privacy 
over traditional face-to-face interviews providing greater anonymity when 
disclosing sensitive information. In the current analysis, the ACASI reports 
captured more drug use than EMA methods. It is hard to differentiate between 
“fuzzy” recall that may have been reported via ACASI (leading to over-reports) 
from participants that may have nodded of when answering the EMA survey 
(leading to under-reports). 
While we document good concordance between EMA methods with both ACASI 
and sweat patch approaches, this analysis neglects to consider a primary analytical 
strength of EMA methodology, namely the examination of real-time drug use.  
EMA methods allow for the examination of the variation and amount of drug use 
by day. ACASI methods are unable to drill down to daily drug using patterns due 
to feasibility issues (study visits, etc.). Despite these differences in methodologies, 
our EMA results remained reliable when compared to ACASI based methods and 
could prove extremely useful in understanding drug use among community 
dwelling, non-treatment seeking chronic drug users.  
Misreporting by EMA 
Relative to sweat patch reports, there were no demographic or behavioral 
correlates of over-reporting of cocaine use by EMA whereas having a stable 
partner, male gender and daily injection at baseline were associated with under–
reporting of cocaine use by EMA. Baseline heroin use was the only significant 
correlate of misreporting of heroin by EMA relative to the sweat patch. In total, 
these data suggest that more regular heroin users were more likely to both over- 
and under-report heroin, raising concerns regarding misclassification due to the 
limitations of sweat patch detection of heroin as highlighted above.  
Relative to ACASI, sharing injection needles was positively associated with EMA 
over-reporting of both cocaine and heroin use, while under-reports of cocaine use 
was positively associated with having medical insurance. In contrast, EMA under-
reporting of heroin use were positively associated with baseline heroin use and 
HIV status. Stable factors, such has having insurance, may lead to underreporting 
of cocaine use as a result of a social desirability bias. The associations of 
misreporting with sharing needles, baseline heroin use and HIV status most likely 
reflects the recruitment criteria of EXACT, which included a large proportion of 
HIV infected individuals with more recent and intense drug use.  
Substance abuse is commonly associated with a chaotic or disordered life, mental 
illness, financial and legal difficulties, and inadequate housing or transportation 
[48-50]. As members of the ALIVE cohort, all EXACT participants had a history 
of abusing illicit drugs and most were HIV infected. Long-term chronic drug 
abuse has physical ramifications but also cognitive effects. Working memory 
deficits are also prominent among HIV infected individuals. During periods of 
intoxication, heroin users suffer a slow drop off in attention and often fall asleep 
[51]. Baseline cocaine and heroin use heavily impacted EMA misreporting of 
heroin use but not cocaine use. It is possible that inattention or sleep may have 
contributed to heroin users (more so than cocaine users) difficulties in recalling 
drug use on a weekly basis (both as over reports and under reports) as was 
required of drug use assessed by ACASI. With respect to EMA under-reporting, 
we found no evidence of exhaustion from using the hand-held devices in reporting 
drug across study week or by drug type. Notwithstanding these differences in 
reporting by drug type, EMA methods captured much of the drug use reported by 
ACASI methods. 
There are several strengths of EMA methods that make them desirable to capture 
illicit drug use among community-dwelling populations. Because they are assessed 
in essentially real-time, EMA does not require individuals to recall or remember 
behaviors for prolonged periods. Social desirability bias is a reporting bias that 
arises when individuals under-report specific behaviors or actions because they 
believe they are sensitive and not socially acceptable to report [52].  ACASI 
methods have been shown to decrease social desirability bias by allowing greater 
respondent privacy because questions are administered audibly and in text on a 
computer screen in a private room without the direct participation of a study 
interviewer [44].  However, EMA methods may allow for even greater respondent 
privacy, as participants are able to answer questions in their natural environment, 
allowing participants to calmly respond to questions where they feel most 
comfortable, away from a study site. ACASI interviews and sweat patches require 
participants to visit study sites at regular intervals.  
For ACASI assessments, a missed visit may mean a whole year passes before 
participants report on their behaviors.  Missing an EMA prompt does not have the 
same impact on data collection; participants have multiple opportunities to self-
cue and self-report specific behaviors as well as respond to surveys throughout the 
day, making the impact of missing one reported event less problematic for 
analyses.  
Additionally, EMA methods can provide more intensive follow-up opportunities 
compared to sweat patch or ACASI assessment. Daily outcome assessments over 
extended periods of time are feasible when using EMA methods because 
participants carry the devices 24 hours a day 7 days a week. Prior studies have 
involved participants using the devices for up to 6-months [25]. Real-time data 
capture allows for the daily context and “situatedness” of drug use to be assessed, 
including information on the number of days used, frequency and amount used in 
a day, as well as participant behaviors that occur due to specific cultural, 
organizational, and structural environments [13].  Historically, ACASI has 
resulted in greater disclosure of sensitive information [42-44] and previous EMA 
analyses by ourselves and others have demonstrated that EMA is capable of 
capturing this type of information as well [23, 24, 26, 30, 53].  
 Assessing drug use in epidemiologic studies must involve an approach that is 
unobtrusive, does not rely on recall, has limited requirements for participant 
participation, and is accessible and affordable. mHealth may provide an excellent 
solution for assessing drug use in the field.  Beyond real-time self-reporting, 
mHealth strategies may include remote monitoring with wearable sensors which 
are currently under evaluation to identify the onset and duration of cocaine use. 
iMStrong (PI Edward Boyer, Univ of Massachusetts Med Sch) is a system 
comprised of an unobtrusive, wearable sensors that continuously record and 
wirelessly transmit physiologic measures (e.g., increased electrodermal activity, 
skin temperature, and motion) of sympathetic nervous system arousal that works 
with a smartphone to alert individuals to the onset of drug cravings. “AutoSense” 
uses a wearable sensor that can collect heart rate, respiration patterns and blood 
alcohol levels in a person’s natural environment [54]. These early prototype 
methods for real-time quantification of illicit drug use will likely evolve to become 
more reliable and proficient, expand accessibility, and be adaptable for measuring 
multiple substances concurrently.  
The level of concordance between EMA and traditional biological and self-report 
methods suggests that utilizing EMA mHealth strategies are feasible for assessing 
drug use among community dwelling, non-treatment seeking drug users. Future 
studies integrating EMA methods with the use of sensors for assessing drug use 
will likely provide both the biological and environmental cues of illicit drug use as 
well as provide a more complete picture of drug using behaviors. 
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* All baseline characteristics represent behavior within the 6 months prior to the start of EXACT 
†HIV+ status was an inclusion criterion for Trials 3 & 4; CD4 & viral load tested on HIV-positive 
participants only.




Sociodemographic Variables N (%) 
Median age, years (IQR) 48.5 (43.3-52.9) 
African American  98(90) 
Male  58 (52) 
High school education  44 (41) 
Never married  66 (61)  
Income, yearly < $5000 83 (78) 
Medical insurance 93 (85) 
Homeless  9(8) 
Have primary care doctor 97 (89) 
Emergency room visit (ER) 28(26) 
Substance Use Variables 
Cigarette use  91 (83) 
Alcohol use  71 (65) 
Marijuana use 27 (25) 
    Cocaine use (any route) 54 (47) 
    Heroin use (any route) 52 (46) 
   Speedball  26 (23) 
    Drug Abuse Screening Test, DAST>16  
Clinical Variables 
    Depressive symptoms (CESD >23)  26 (23) 
Methadone treatment  26 (23) 
Hepatitis C virus seropositive  94 (86) 
HIV positive †  64 (59) 
    Median CD4 (IQR)† 360.5 (239-529) 
HIV viral load > 500 copies/mL †  35 (55) 
Any retroviral therapy 42(65) 
Figure 2.1: Reported drug use by ACASI, EMA and sweat patch methods 
Figure 2.1. Counts of weeks of reported drug use as assessed by sweat patch (green bars), EMA (orange 
bars) or ACASI (blue bars) method 
Figure 2.2: Percent agreement by drug type and week comparing EMA, sweat 
patch and ACASI methods 
Figure 2.2. Percent agreement by drug type and week comparing EMA, sweat patch and ACASI methods. 
Panel A: Percent agreement between EMA/Sweat Patch methods (blue bars) and EMA/ACASI methods 
(green bars) by week for cocaine use. Panel B: Percent agreement between EMA/Sweat Patch methods 
(orange bars) and EMA/ACASI methods (grey bars) by week for heroin use.
Table 2.2:  Percent agreement, over and underreporting of EMA responses 
compared to sweat patch and ACASI response by drug type 
Cocaine Heroin 
N % N % 
Reported yes on 
EMA/sweat patch 
negative 
30 9% 70 19% (Over report) 
EMA & Sweat 
Patch concordant 298 70% 307 72% 
Reported no on 
EMA/sweat patch 
positive 
79 21% 28 8% (Underreport) 
Reported yes on 
EMA/ACASI 
negative 
29 8% 33 9% (Over report) 
EMA & ACASI 
concordant 327 77% 335 79% 
Reported no on 
EMA/ACASI 
positive 
58 15% 49 13% (Underreport) 
Figure 2.3: Frequency of cocaine (A) and heroin (B) use by week as reported by 
EMA and ACASI methods  
A. 
B. 
Figure 2.3. Frequency of cocaine and heroin use by study week as reported by EMA and ACASI methods. 
Plot A: Box plots of the median, 25th and 75th percentiles of self-reported frequencies of cocaine use by 
week as assessed by ACASI (blue boxes) and EMA (red boxes) methods. Plot B:  Box plots of the median, 
25th and 75th percentiles of self-reported frequencies of heroin use by week as assessed by ACASI (green 
boxes) and EMA (orange boxes) methods.
Table 2.3: Correlates of misreporting cocaine and heroin by EMA compared to 
sweat patch (A) or ACASI (B) methods* 
* Correlates included in multivariable models had p-values<0.1 in univariate analyses and represent
behaviors occurring within the 6 months prior to the start of EXACT 
Bold values indicate statistical significance, p-value<0.05 











aOR (95%CI) aOR (95%CI) aOR (95%CI) aOR (95%CI) 
Female 0.47 (0.23-.98) 0.31(0.08-1.1) + 
Age≥50 0.52(0.24-1.14) 
Never Married 0.51(0.25-1.07) + 0.68(0.21-2.19) 
Alcohol Use 1.55(0.72-3.36) 
Insurance 3.15(0.76-13.05) 
Any heroin 2.10(1.0-4.56) 5.56 (1.37-22.46) 
Any cocaine 1.55(0.72-3.36) 1.68(0.79-3.62) 
Same doctor for at least 2 
years 0.60(0.30-1.23) 










aOR (95%CI) aOR (95%CI) aOR (95%CI) aOR (95%CI) 
Age≥50 0.42(0.17-1.07) + 
Never Married 0.47(0.21-1.02)+ 0.53(0.24-1.18) 
Cigarette use 2.73(0.64-11.72) 2.88(0.61-13.57) 2.76(0.46-16.55) 
Alcohol use 1.73(0.69-4.29) 
Insurance 6.62(1.16-37.76) 
Any heroin 0.77(0.29-1.99) 3.04(1.33-6.95) 
Any cocaine 1.78(0.76-4.20) 1.86(0.77-4.51) 1.19(0.53-2.68) 
HIV infected 0.52(0.18-1.5) 4.56(1.80-11.58) 
Shared needles 2.79(1.03-7.5) 2.96(1.17-7.51) 
Primary care physician 0.57(0.15-2.14) 
Yearly income<$5,000 1.69(0.45-6.34) 
Chapter 3:  
Utilizing mHealth to Identify Illicit Drug Users at Risk for 




Background: We examined whether mobile health (mHealth) methods of 
collecting data in real-time could effectively identify drug users with high-risk 
drug use behavior, and whether these high-risk drug users had indicators of poorer 
engagement in care. 
 
Methodology: Participants from the AIDS Linked to the IntraVenous Experience 
(ALIVE) study in Baltimore, MD were recruited into the EXposure Assessment in 
Current Time (EXACT) study. Participants were given a mobile device for 
assessment of their daily drug use (heroin, cocaine or both), mood and social 
context for a 4-week period.  Real-time, self-reported drug use events were 
summed for each individual by day and drug use risk was assessed through latent 
class growth mixture models. Latent class regression examined the association of 
mHealth-defined risk groups with sociodemographic and clinical characteristics 
and with indicators of engagement in care. 
 
Results: 109 participants were a median of 48.5 years old, 90% African 
American, 52% male and 59% HIV-infected. Growth mixture modeling identified 
three distinct classes: low intensity drug use (25%), moderate intensity drug use 
(65%) and high intensity drug use  (10%). Individuals classified as high intensity 
users were younger, injected greater than once per day and shared needles, relative 
to the low intensity drug using class. At the subsequent ALIVE visit, individuals 
classified as high intensity drug users were nine times less likely to be medically 
insured (adjusted OR: 0.10, 95%CI: 0.01-0.88) and were at greater risk for failing 
to attend any outpatient appointments (aOR: 0.13, 95%CI: 0.02-0.85) relative to 
low intensity drug users. 
Conclusions:  Real-time collection of drug use EMA data using mobile devices 
identified a distinct class of drug users with high-risk behavior at risk for poor 
engagement in care. mHealth monitoring holds promise for identifying high-risk 
persons and potentially targeting and efficiently delivering  real-time interventions 
to improve drug treatment and HIV care outcomes. 
Introduction 
Optimal engagement in HIV care is characterized by swift linkage and enrollment 
after diagnosis, prolonged retention in care, and sustained adherence to prescribed 
antiretroviral therapy (ART) regimens [1]. Individuals with substance abuse 
problems tend to have a range of vulnerabilities that increase their risk of both 
becoming HIV infected and failing to achieve the desired treatment outcome of 
viral suppression.  Regardless of HIV status, engagement in health care entails 
specific actions that individuals must take to achieve the best outcomes from 
available health care services [2]; for example, having a primary care physician 
and regularly attending outpatient appointments rather than utilizing the 
emergency department for primary care needs(which is exceedingly expensive) . 
People who inject drugs (PWID) are often poorly engaged in care due to the 
multiple contributing factors of prolonged substance abuse, mental health 
disorders, HIV and hepatitis C virus (HCV) infection, unstable housing, violence, 
poverty and incarceration [3-5]. Identifying drug users at risk for poor engagement 
in care could allow for targeted and tailored interventions to foster engagement 
and prevent needless morbidity and mortality.  
In epidemiologic studies, ascertainment of illicit drug use is commonly by self-
report, which lends the data susceptible to substantial recall bias, particularly when 
captured within broad time periods (e.g., “any drug use in the past year”) [4, 6, 7].  
Further, details regarding the intensity and patterns of drug use are rarely captured 
[8, 9]. These recall methods are limited in their ability to identify periods of daily 
intense or intermittent use and fail to capture the context of an individual’s drug 
using experience. 
 
Ecological Momentary Assessment (EMA) methods are able to collect patient-
level data in real time as well as facilitate responsive communication between 
clinic and patient utilizing smart phones or hand-held devices. These mobile health 
(mHealth) methods have been utilized in smoking cession studies [10-15] and in 
methadone-maintained outpatient drug users to examine activities associated with 
cocaine and heroin use [11, 16-20].  Detailed, longitudinal EMA data can provide 
information at varying time intervals (e.g. hourly, daily, weekly) of the changes 
and patterns of behaviors that are often not static over longer periods of time. By 
assessing participants in real-time, EMA studies can reduce recall biases and 
distinguish behavioral nuances that are not captured at periodic study visits every 
6 months or yearly as performed in many traditional cohort studies.  
 
For many health-related conditions, long-term assessments (e.g. longitudinal data) 
are necessary to derive meaningful associations between exposures and outcomes 
as well as to describe heterogeneous patterns of exposure. Analytic methods, such 
as growth mixture modeling, have been previously used to identify distinct 
trajectories of drug using behavior over extended periods of time [21-23] but these 
methods have yet to be widely applied to EMA data.  
 
To our knowledge, the current analysis is the first to utilize EMA methods to 
ascertain 30-day drug-using trajectories among a sample of drug users in 
Baltimore, MD and to identify sociodemographic and behavioral predictors of 
these drug-using trajectories. Finally, we evaluated whether EMA-derived drug 





EXACT study participants 
Exposure Assessment in Current Time (EXACT) study participants were recruited 
from the AIDS Linked to the IntraVenous Experience (ALIVE) study, an on-
going, community-recruited, observational cohort of over 3,000 persons with a 
history of injecting drugs in Baltimore, MD[24]. The ALIVE cohort is 
community-based rather than clinic-based, thereby avoiding selection bias toward 
persons seeking or accessing care. Details of the EXACT study have been 
previously described [25], and included four successive trials conducted from 
November 2008 through May 2013. Each trial was planned to follow 30 
participants each for 30 days. 
 
Eligibility criteria for EXACT included current enrollment in ALIVE and the 
ability to understand and follow directions on a personal digital assistant (PDA) or 
mobile phone.  Individuals were excluded if they had any medical conditions that 
would prevent them from operating the hand held device (e.g., vision or hearing 
impairment) or failed to attend the screening appointment where they were trained 
on how to use the device.  
 
In each trial, the specific inclusion criteria regarding drug use and HIV status were 
varied slightly to ensure a diverse sample and drug use included any route of 
administration (injection and non-injection).  In Trial 1, selection was made to 
balance the numbers of participants that reported heroin or cocaine use within the 
past month (defined as recent drug use) with those that were not currently using 
drugs. In Trial 2, all participants reported heroin or cocaine use within the prior 
three months. While HIV status was not a recruitment criterion in the first two 
trials, Trial 3 included only HIV-infected participants with recent heroin and 
cocaine use. These same criteria were also used in Trial 4, but the data collection 
was transitioned from a PDA to a smartphone platform [25].  Participants from all 
trials are included in this analysis. 
The Johns Hopkins School of Public Health Institutional Review Board 
approved the study protocols. All participants in the EXACT study 
provided written informed consent and were informed that involvement (or 
non-involvement) in EXACT would in no way affect their participation in 
ALIVE.  
Data 
Hand-held devices delivered four prompts to complete surveys at random times 
daily between 8am and 9pm (known as random-prompt entries), and one end-of-
day (around 9 pm) survey for 30 days of observation. Participants were also asked 
to self-initiate a survey and self-report each time they either craved (but refrained 
from using) or used heroin or cocaine (or both) in any manner (smoked, snorted or 
injected); these responses represent event-contingent entries. Heroin only and 
cocaine only reports incorporated all reports of heroin or cocaine use respectively, 
including those when used jointly with another drug.   
 
For each event, participants answered questions concerning their drug use, current 
mood, social, physical and activity environment, using survey instruments adapted 
from previous EMA studies [16-20].   To ensure responses to event-contingent 
surveys were recorded in real-time, participants were required to indicate that the 
craving or use had occurred within the prior 30 minutes. All data used in the 
present analyses are from event-contingent entries from all trials.  
 
For Trials 1-3, participants were provided personal digital assistants (PDA, Palm 
Z22, Palm, Inc., Sunnyvale, CA, USA) running applications developed using 
Satellite Forms software (http://www.satelliteforms.net/). All PDA programs were 
disabled except for study-required applications. In Trial 4, participants were 
provided an Android Smartphone (Motorola Droid X2), running an application 
developed using the electronic mobile comprehensive health application (emocha), 
mHealth platform, created at Johns Hopkins School of Medicine. Previously, 
emocha had been used to support community health workers in resource limited 
settings heavily impacted by HIV [26] and was modified specifically for this 
study. 
Exposure data were additionally obtained from audio-computer assisted self- 
interviews (ACASI) completed at enrollment into EXACT or from the existing 
ALIVE database which includes sociodemographic, behavioral, and clinical data 
obtained during biannual study visits. In addition to sociodemographic variables 
(e.g., age, sex, race, education, marital status, employment, income, homelessness 
and health insurance status), baseline data collection included self-reported 
alcohol, tobacco and illicit drug use [as assessed by a score ≥16 via the 28-item 
Drug Abuse Screening Test (DAST)], and depressive symptoms [as assessed by a 
score ≥23 via the Center for Epidemiologic Studies- Depression Scale (CES-D)] in 
the prior 6 months [27].  
Statistical Analyses: 
The outcome of this analysis was number of self-reported heroin and/or cocaine 
use events per day over 30 consecutive days. As a first step, we examined the 
individual patterns of daily drug use overall and by type of drug used. To further 
characterize heterogeneous patterns of drug use, the data were modeled using 
semi-parametric latent class growth mixture models [28, 29], specifically the zero-
inflated Poisson model (ZIP) since the outcome was a count with an excess of zero 
totals.  This approach was used to classify participants into different groups, each 
representing different subpopulations with unique longitudinal patterns. Although 
the number of groups can be hypothesized a priori, one aim of this method is to 
determine the number of meaningful groups that exist in the population. Selecting 
the number of groups involved fitting a series of iterative models, varying the 
number of groups up to 4. Models were compared using the Bayesian Information 
Criterion (BIC), the average posterior probabilities of group membership and the 
usefulness of the number of groups in practice [30, 31]. Group membership was 
assigned by maximum posterior probability and groups were labeled based on 
group characteristics. Backward selection of the parameters representing time 
(e.g., linear, quadratic, cubic) was used to determine trajectory shapes and 
parameters were removed on the basis of statistical significance (P ≤ 0.05).  
 
Baseline sociodemographic and behavioral characteristics were included as time-
fixed covariates in bivariate analyses to describe the increase in relative odds of 
being in a trajectory group (relative to the lowest risk group) per unit increase in 
the risk factor. The limited sample size prohibited multivariable analyses. 
Logistic regression methods were utilized to examine if EMA classes could 
predict key indicators of engagement in care at the next ALIVE visit (5 months 
after EXACT was completed). These outcomes included having any medical 
insurance or attending outpatient physician visits. Other predictors of engagement 
in care included baseline sociodemographic and behavioral characteristics. 
Analyses were performed using STATA 12 (Stata Statistical Software, College 
Station, Texas) and SAS 9.2 (Proc Traj; SAS Institute Inc., Cary, North Carolina). 
Results 
Table 3.1 provides baseline characteristic data for the 109 participants enrolled in 
EXACT. The median age was 48.5 years (inter-quartile range (IQR): 43-53 years), 
90% were African American, 52% male and 59% were infected with HIV. Prior to 
EXACT, 77% of participants reported earning less than $5,000 in annual income, 
23% of participants reported recent methadone treatment and 23% had substantial 
depressive symptoms with a score of 23 or above on the CES-D. Almost ninety 
percent (89%) reported they had a primary care physician at baseline. At study 
entry, 65% of participants reported recent alcohol consumption and 83% reported 
smoking cigarettes daily in the prior six-months.  
The 109 EXACT participants were followed for a median of 28 days (IQR 26-29), 
during which time 98 (90%) participants reported using heroin or cocaine (in any 
manner) at least once while 11 (10%) did not report any drug use. The median 
number of self-reported craving events was 8 (IQR 5-14) and the median number 
of self-reported drug using events was 4 (IQR 1-10). Of 844 total drug use events, 
351 (41.6%) were exclusively heroin, 289 (34.2%) were exclusively cocaine and 
201 (23.8%) were reports of concurrently using both heroin and cocaine.  
 
Figure 3.1 displays lattice plots (also known as heat maps) of the daily intensity of 
any self-reported drug use (Panel A), heroin use (Panel B) and cocaine use (Panel 
C) of EXACT participants over the 30 days of follow-up. Only participants 
reporting drug use were included in these figures (persons with cravings only were 
excluded). Individuals are represented on the y-axis and the color intensity 
indicates the intensity of self-reported drug use for any given day (darker colors 
represent more reports of drug use).  
 
Among individuals self-reporting any drug use (Figure 3.1, Panel A), the mean 
number of drug-using days during study follow-up was 7.7 (standard deviation 
[SD] +/-6.7 days), with a range of 1-28 days. Over the 30-day follow-up period, 
the mean number of drug use events was 11 (SD +/-16); the median number was 
6.5 events (IQR 3-13), with a range of 1-105 reports.  
 
Among individuals self-reporting heroin use (Figure 3.1, Panel B) the mean 
number of heroin-using days over follow-up was 6.6 days (SD+/- 6.5days). Over 
the 30-day follow-up period, the mean number of heroin use events was 10 (SD 
+/-15.1); the median number of heroin use events was 4.5 (IQR 2.0-10.5), and a 
maximum of 93 heroin use events were reported over follow-up.  The greatest 
number of heroin use events in any one day was 7. 
 
On average, cocaine use was reported on 6.2 days (SD +/-5.3 days) during follow-
up (Figure 3.1, Panel C).  Among all participants reporting cocaine use, an average 
of 8 (SD+/- 9.5) cocaine use events, a median of 4 (IQR 3-10) cocaine use events, 
and a maximum of 61 cocaine use events were reported over the 30 days of 
EXACT. The greatest number of cocaine events reported in any one day was 5. 
 
EMA-defined drug using risk groups 
Mean drug use per day was examined using semi-parametric growth mixture 
models with 2, 3, and 4 groups and time modeled linearly.  Despite the slightly 
better fit provided by the 2-group model (as evidenced by the largest negative 
BIC), the 3-group unadjusted model was chosen as the final model for the 
observed data (BIC 2-group= -1241.9, BIC 3-group= -1182.8, BIC 4-group= -
1162.1) as it defined three interpretable and relevant subgroups with a low BIC. 
The groups were labeled for convenience based on their profiles of response as: 
low intensity drug use (Group 1), moderate intensity drug use (Group 2) and high 
intensity drug use (multiple uses per day, Group 3). The average probability of 
most likely group membership was between 0.87 and 0.96 indicating a high degree 
of classification accuracy and exceeding the threshold of 0.70 suggested for these 
methods [32]. 
 
Figure 3.2 displays the trajectories of drug use over time based on the 3-group 
model. Although cubic and quadratic fits were explored, all three groups were best 
fit with linear trajectories. Group 1 represented 25.0% of the participants with a 
mean of 0 drug use events per day (SD +/- 0.04). The moderate intensity drug-
using group (Group 2) comprised approximately 65.0% of participants and was 
marked by an overall average of less than 1 (SD +/- 0.19) drug use events per day 
(SD +/-0.19), with a slight decline over the study period.  Group 3 represented 
individuals using drugs multiple times daily (10.5% of participants). This group 
was marked by an overall average of 1.5 drug use events per day (SD +/- 0.85).   
 
Sociodemographic and behavioral characteristics of drug using risk groups: 
Factors associated with membership in the EMA-defined drug-using risk groups 
were examined by separately comparing Group 2 (moderate intensity users) and 
Group 3 (high intensity users) to the Group 1 participants with stably low to no 
reported drug use as the referent group (Table 3.2). Moderate intensity drug users 
(Group 2) had lower odds of being married (log Odds Ratio (log OR): -1.48, p-
value=0.036) and increased odds of being a current injector (log OR injecting 
≥1/day: 2.17, p-value=0.049), injecting heroin (log OR: 2.26, p-value=0.007) and 
using crack (log OR: 2.60, p-value=0.015) relative to Group 1.  High intensity 
drug users (Group 3) were more likely to be younger (log OR: -2.11, p-
value=0.068), share needles (log OR: 2.70, p-value=0.0296) and inject cocaine 
(log OR: 2.34, p-value=0.028), inject heroin (log OR: 3.31, p-value=0.003), use 
crack (log OR: 3.25, p-value=0.009) and speedball (log OR: 2.70, p-value=0.043) 
relative to those in Group 1.  Additionally, compared to individuals reporting low 
intensity drug use, high intensity drug users had lower odds of being HIV positive 
(log OR: -1.94, p-value=0.042). 
 
Associations of drug using risk groups with subsequent engagement in care 
indicators 
We next examined the association of EMA-classified drug using risk groups with 
subsequent engagement in care outcomes as determined through the ALIVE study 
follow-up. At the first ALIVE study visit following EXACT study completion, 
84% of EXACT participants reported having medical insurance of any kind 
(private or public) and 72% reported attending an outpatient medical appointment.   
In unadjusted analyses (Table 3.3), high intensity drug users (Group 3) were 79% 
less likely to report attending outpatient appointments relative to low intensity 
drug users (OR: 0.19; 95% confidence interval [CI], 0.03-1.04). Additionally, 
compared to low intensity drug users, high intensity drug users had lower odds of 
having medical insurance (OR: 0.19; 95% CI, 0.03-1.04) 
 
In adjusted analyses (Table 3.4), the final model for being engaged in care 
(defined as reporting subsequent outpatient visits and having medical insurance) 
included drug use intensity groups, being older, female gender, homelessness and 
recent methadone treatment. Adjusting for these covariates, individuals in the high 
intensity drug-using group reported an 88% reduced likelihood  (aOR 0.12; 95% 
CI, 0.02-0.85) of reporting outpatient visits relative to low intensity users.  
Compared to low intensity users, high intensity drug users were also less likely to 




Our results demonstrated that collecting self-reported drug using data utilizing 
Ecological Momentary Assessment (EMA) methods allowed for an in-depth 
understanding of the heterogeneous patterns of drug use and associated behaviors. 
Growth mixture modeling of real-time reports of daily heroin or cocaine use over 
a 30 day study period distinguished three drug using risk groups, represented as 
low, moderate and high intensity drug use.  Our analysis demonstrated distinct 
behavioral profiles for each risk group with the high intensity users comprised of 
younger, polysubstance users who more likely to share needles but not to be HIV 
infected.  Importantly, during subsequent follow-up the drug using groups we 
identified were predictive of indicators of poor engagement in care. These findings 
provide a richer and more informed understanding of individual trajectories of 
drug use. Drug-use patterns obtained through mHealth approaches may provide a 
platform for future development of personalized, context-sensitive interventions 
(Ecological Momentary Interventions, EMI) for HIV treatment and drug cessation 
programs. 
Studies of HIV-infected drug users often simplistically categorize persons into a 
broad IDU risk group irrespective of recency, type or intensity of use. All 
participants of the EXACT Study reported injecting drugs at some point within the 
prior six months, as they are members of the ALIVE study. Other epidemiologic 
studies crudely define drug use as “any drug use” during a specified time interval, 
commonly over the prior 6 months to a year [4, 6, 7]. In drug treatment studies, 
drug use is often categorized as any use compared to cessation, although measures 
of drug use intensity are becoming of interest (e.g., number of days used in the 
past month). This analysis demonstrated the average number of days used in the 
past month to be approximately 8. None of these methods describe the severity or 
timing of drug use. Our EMA data provided more refined assessments of drug 
using behavior, including daily intense or intermittent use. This is what makes 
EMA data unique, the ability to capture more refined assessments of drug using 
behavior. As a result, our analyses were able to demonstrate the presence of non-
uniformity in drug using risk that varied by sociodemographics, drug type, and 
frequency of daily use. 
The three drug using risk groups defined in this analysis represent individuals with 
increasing intensity of heroin or cocaine use. A quarter of study participants were 
in the low intensity drug-using group as they reported little heroin or cocaine use 
over the 30-day follow-up. This is an expected finding based on the eligibility 
criteria which aimed to recruit participants with variable intensities of drug use. 
Even among our population of self-identified injection drug users, this analysis 
found a low intensity drug using group, which provided a baseline for 
comparisons between groups represented by varying intensities of heroin and 
cocaine use. This also highlights the need for community-based samples as these 
low intensity users are rarely seen in drug treatment studies.  
The moderate intensity drug-using trajectory had the largest membership, was 
associated with prior injecting heroin and smoking crack relative to the low 
intensity drug-using group. Despite polyroute drug use, these individuals reported 
less than daily drug use over follow-up and no behaviors associated with HIV risk 
including sharing syringes, all of which may represent reduced drug addiction [33, 
34]. Interestingly at baseline, injecting more than once a day (not drug specific) 
was associated with membership in this group. This could be a result of recall bias 
that is common in cohort studies semi-annual study visits. At the baseline, 
participants were asked to recall their injection drug using behavior in the prior 6-
months and these behaviors did not uniformly match what participants reported in 
real-time.  This discrepancy in reporting may provide insight into how drug 
addiction is characterized and quantified. Rather than rely on baseline assessments 
of injection behaviors, drug type and intensity of use may provide better insight to 
an individuals drug-using risk. Overall, the behavioral characteristics of this group 
suggest its members are individuals who are stable but chronic drug users who 
remain at risk for drug use-related comorbidities and overdose.  
Membership in the high intensity drug-using group was associated with younger 
age and self-reports of injecting drugs greater than once per day. Relative to the 
low intensity drug users, sharing needles and the use of a variety of drugs, 
including heroin and cocaine separately, injecting both together as speedball, and 
smoking crack were associated with group membership. High frequency of poly-
drug use and needle sharing is not only associated with longer time to cessation 
[33] but puts individuals at risk for the medical consequences of chronic substance 
abuse including HIV transmission or acquisition and poor treatment outcomes 
[35].  
Surprisingly, members of the consistently high drug-using trajectory were less 
likely to be infected with HIV. Our analysis demonstrated that individuals who are 
high-risk users are young, intense drug users who remain at risk for HIV 
acquisition. In ALIVE, the risk of acquiring HIV from injection drug use has 
declined in recent years [36]. As a result, there is less circulating HIV and the risk 
for transmission from a single injection event has reduced. The paradoxical 
reduced HIV prevalence among high intensity users may represent a cohort effect 
of younger more intense users with distinct social networks from older users [37] 
who, by nature of declining HIV prevalence have been spared from acquiring 
HIV. However, as we have seen with hepatitis C infection, HIV risk may simply 
be deferred rather than obviated [38]. Our results suggest that these methods could 
be used in drug treatment trials to calculate daily intensity of use and to capture 
how intensity relates to other drug using related behaviors (e.g. participation at 
shooting galleries or sharing needles). 
Drug-seeking behavior often conflicts with the health promoting goals of safer 
sex, safer injecting, and adherence to recommended treatments. Our adjusted 
analysis demonstrated that the odds of having medical insurance and of attending 
outpatient appointments were reduced for those classified as high intense drug 
users relative to low intensity drug users even after adjustment for potential 
confounders. Our EMA-defined risk groups displayed clinical relevance as 
evidenced by their ability to predict engagement in care; moving forward, these 
risk groups could help with targeting of resources for those who have difficulties 
of remaining engaged in care. 
In addition to relatively small sample size, we were limited in this analysis by 
examination of only time-fixed baseline factors and behavioral variables as 
predictors of class membership. The latter was done intentionally in order to 
determine what stable factors predicted drug use, as inclusion of time-varying 
covariates would have only affected the shape of the trajectory rather than 
membership in the groups [29].  Additionally, there may be a concern that our 
study population consists of mostly older individuals who may be maturing out of 
their drug use and/or beginning to transition to use of prescription drugs rather 
than injection of street drugs. While this may be true, our study population is 
representative of the aging population of drug-users in Baltimore, MD and many 
other cities nationally (e.g., Philadelphia, Newark, Detroit)[39]. 
To our knowledge, this is one of the first mHealth analyses to use semi-parametric 
growth mixture models with EMA data to examine sub-populations of heroin and 
cocaine users. While growth mixture modeling has been previously used to 
describe trajectories of drug use and cessation, these analyses have been 
retrospective with decades of follow-up [21, 23] and did not employ ecological 
momentary assessment methods. Studies have examined latent classes of drug use 
[22, 40-42] where the goal was to create meaningful subgroups (or latent classes) 
of drug use based on similarities in responses to a set of indicators but did not 
describe the pattern of drug use intensity over time (a hallmark of growth mixture 
modeling). Our analysis described drug use from EMA self-reports and employed 
growth mixture models to describe the meaningful groups of drug users that 
existed in the population.  
 
Although complex, our growth mixture modeling methods still only focus on 
mean daily drug-using patterns over a relatively short period of observation rather 
than the specific drug using events. A long term objective of this work is to 
develop more refined estimates of drug use risk with the goal of reaching smaller 
time intervals that would better predict immediate behaviors like relapse or missed 
ART doses. 
 
As previously reported, the EXACT study demonstrates the ability to efficiently 
and effectively collect high-quality, real-time EMA data in a challenging study 
population of impoverished urban drug users [25]. As drug use is often not well 
captured in epidemiological studies, our research demonstrates the ability of 
mHealth methods to capture drug use in real-time and identify higher-risk drug 
users. Combined with sophisticated analytic methods, these EMA data described 
drug use intensity patterns, which have implications for risk behavior and other 
clinical outcomes including engagement in care. In contrast to the broad range of 
possibilities of mHealth applications among HIV and substance users, the current 
EMA analysis should be considered as an initial application. EMA methods 
improve data collection techniques as well as expand approaches to delivering 
interventions, such as providing the ability to capture the environmental context of 
an individual’s drug using experience (Linas et al. under review). In the near 
future, novel mHealth intervention strategies directed at improving substance 
abuse and HIV treatment outcomes may incorporate biosensors for drug use or 
adherence monitoring and geographical positioning systems for location-based 
individualized ecologic momentary interventions.  
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* All baseline characteristics represent behavior within the 6 months prior to the start of EXACT
Δ Recent drug use was part of the inclusion criteria for Field Trials 3 & 4. Drug use includes any route of 
administration (smoking, snorting, and injecting). 
++ HIV+ status was part of the inclusion criteria for Field Trials 3 & 4. 
+ CD4 & viral load based on HIV-infected participants only. 
Table 3.1:  Baseline characteristics of EXACT participants* 
Characteristic N % 
Median Age, IQR 48.5 (43-53) - 
Male 58 52 
African American 98 90 
Never Married 66 61 
High School Education 44 40 
Alcohol use 71 65 
CES-D>23 26 23 
Cigarette use 91 83 
<1/2 pack cigarettes per day 20 18 
>1/2 pack cigarettes per day 71 65 
Income<$5,000 83 77 
Homeless 9 8 
Medical Insurance 93 85 
Have a primary care doctor 97 89 
Drug abuse, DAST>16 6 18 
Methadone Treatment 26 23 
Marijuana use 27 24 
Speedball use* 26 23 
Heroin use (any route) Δ 52 46 
Cocaine use (any route) Δ 54 47 
Hepatitis C positive 94 86 
HIV positive++ 64 59 
     Median CD4 (IQR)+ 360.5(239-529) - 
     Viral Load>500+ 35 55 
A.                       B.  C. 
Figure 3.1: Lattice plots of individual drug use intensity by day and drug type 
Panel A: Any heroin or cocaine use intensity by trial day. B. Any heroin use intensity by trial day.  C. Any cocaine use intensity by trial day. Individuals are 
















































































































































































































































Figure 3.2: 3-Class unadjusted growth mixture model of mean daily drug use in 
EXACT  
Figure 3.2: Trajectories of mean drug use per day among 109 illicit drug users in the Exposure Assessment 
in Current Time (EXACT) study. The y-axis represents the mean number of drug use events per day; the x-
axis represents each day of the trial. The solid lines represent the predicted mean use per day given group 
membership with their respective 95% confidence intervals shown as dotted black lines. The solid dots 
represent the observed mean use per day given group membership. The 3 groups (and proportion of total 
population within each group) represent: blue, low intensity drug use (25.0%); red, moderate intensity drug 
use (64.7%); green, high intensity drug use (10.4%). All trajectories were modeled linearly. 
*All characteristics represent self-reported behavior within the 6 months prior to the start of EXACT
a. Center for Epidemiologic Studies- Depression Scale
b. Drug Abuse Screening Test
Table 3.2: Risk factors associated with drug use risk group membership 
relative to low intensity drug using group* 
EXACT EMA Drug Use Risk Groups 
Risk factor Group 2-Moderate intensity drug use Group 3-High intensity drug use 
Log Odds SE p-value Log Odds SE p-value 
Demographics 
Age≥50 -0.61 0.58 0.2892 -2.11 1.16 0.0685 
Female -0.17 0.55 0.7554 0.60 1.04 0.5641 
Black -0.23 1.02 0.8253 -1.34 1.21 0.2698 
Never married -1.48 0.71 0.0365 -1.28 0.93 0.1706 
High school educated 0.24 0.59 0.684 -1.41 1.16 0.2227 
Income<$5,000 0.99 0.64 0.1248 1.33 1.18 0.2619 
Homeless -1.06 0.84 0.2072 -0.72 1.39 0.6039 
Any alcohol use 0.29 0.62 0.6438 0.72 0.95 0.4475 
Any cigarette use 0.62 0.71 0.3829 17.13 3211.04 0.9957 
Clinical Characteristics 
Have a usual source of care -17.00 2878.31 0.9953 -17.31 2878.31 0.9952 
Same doctor 90% of the time -17.26 2984.56 0.9954 -17.42 2984.56 0.9953 
Same doctor for at least 2 years -0.50 0.63 0.4328 -0.12 0.92 0.8983 
CES-D≥23a 0.17 0.66 0.7979 1.39 0.88 0.1161 
HIV -0.58 0.60 0.34 -1.94 0.95 0.0418 
Highly active antiretroviral 
therapy (HAART) -12.55 454.98 0.978 -14.92 454.99 0.9739 
Hepatitis C antibody positive 0.07 0.83 0.9308 -1.60 1.02 0.1182 
Sexually transmitted infections 
(excluding chlamydia) -17.31 2593.91 0.99 -10.84428 229.9665 0.9624 
Drug use characteristics 
Frequency of daily injection 
     <1/day 1.92 0.74 0.009 -14.38 2798.93 0.9959 
     ≥1/day 2.17 1.10 0.0492 3.75 1.36 0.006 
Shared needles 2.02 1.08 0.063 2.70 1.24 0.0296 
Current injector 1.92 0.66 0.0039 2.75 1.00 0.0063 
Marijuana use 0.82 0.65 0.2089 -0.11 1.19 0.9261 
Snort cocaine 16.03 2805.64 0.9954 16.84 2805.64 0.9952 
Snort heroin 18.07 2727.37 0.9947 17.10 2727.37 0.995 
Inject cocaine 1.17 0.91 0.2022 2.34 1.07 0.0284 
Inject heroin 2.26 0.84 0.0072 3.31 1.13 0.0035 
Crack use 2.60 1.07 0.0153 3.25 1.24 0.0092 
Speedball use 2.02 1.21 0.0943 2.70 1.33 0.0435 
Attended a detox program 17.14 2808.83 0.9951 16.75 2808.83 0.9952 
Methadone treatment -0.29 0.64 0.6453 -1.57 1.51 0.2994 
Any other drug treatment program -0.83 0.78 0.2889 -16.99 3135.07 0.9957 
Attended a drug alcohol treatment 
program -0.02 0.58 0.9682 -1.34 0.95 0.1578 
DAST ≥16b 0.49 1.33 0.715 0.82 1.68 0.627 
Table 3.3: Unadjusted association of drug use risk and engagement in care at 
subsequent ALIVE visit 
*Bold values indicate p-value<0.05  
At subsequent ALIVE Visit, did 
Participant report…. Medical Insurance Status 
Attended Outpatient 
Appointments 
 OR 95% CI P-value OR 95% CI P-value 
EMA drug use risk groups       
Low intensity drug use Ref Ref  Ref Ref  
Moderate intensity drug use 0.64 0.13-3.19 0.558 0.64 0.19-2.16 0.476 
High intensity drug use 0.13 0.02-0.94 0.043 0.19 0.03-1.04 0.055 
Table 3.4: Adjusted associations of drug use risk and engagement in care at 
subsequent ALIVE visita 
Models adjusted for variables with listed values 
*Bold values indicate p-value<0.05
 
At subsequent ALIVE 
Visit, did Participant 
report…. Medical Insurance Status Attended Outpatient Appointments 
 aOR 95% CI P-value aOR 95% CI P-value 
EMA drug use risk 




Low intensity drug use Ref Ref Ref Ref Ref Ref 
Moderate intensity drug 
use 0.50 0.09-2.89 0.486 0.52 0.14-1.89 0.322 
High intensity drug use 0.10 0.01-0.88 0.040 0.13 0.02-0.85 0.033 
       
Female 0.69 0.21-2.33 0.554 2.93 1.07-8.04 0.037 
Age≥50 1.24 0.32-4.84 0.757 0.68 0.25-1.88 0.460 
Homeless 0.62 0.07-5.28 0.663 0.42 0.07-2.58 0.350 
Methadone Treatment    0.74 0.23-2.35 0.604 
Same doctor for at least 2 
years 5.57 1.63-19.05 0.006    
Chapter 4:   
Capturing illicit drug use where and when it happens: an 
ecological momentary assessment of the social, physical and 
activity environment of using versus craving illicit 
 
Abstract 
Aims: Understanding the environmental influences of using versus craving (but 
resisting) illicit drugs can inform interventions to prevent relapse and support 
cessation.  
 
Design: The Exposure Assessment in Current Time (EXACT) study utilized 
ecological momentary assessment methods to assess drug use in real-time in 
participants’ natural environments. 109 participants were provided mobile devices 
and asked to self-report every time they either craved (without using) or used 
heroin or cocaine for 30-days from November 2008 through May 2013.  
 
Setting: Baltimore, MD 
 
Measurements: For each event, participants answered questions concerning their 
drug use, current mood, and their social, physical and activity environments. Odds 
ratios of drug use versus craving were obtained from logistic regression models 
with generalized estimating equations of all reported events.   
 
Findings: Participants were a median of 48.5 years old, 90% African American, 
52% male and 59% HIV-infected. Participants were significantly more likely to 
report use rather than craving drugs if they were with someone who was using 
drugs (aOR1.45, 95% CI: 1.13,1.86), in an abandoned space (aOR 6.65, 95% CI: 
1.78,24.84) or walking/wandering (aOR 1.68, 95% CI: 1.11,2.54). Craving drugs 
was associated with being with a child (aOR 0.26; 95% CI: 0.12,0.59), eating 
(aOR 0.54, 95% CI: 0.34,0.85) or being at the doctor’s office (aOR 0.31, 95% CI: 
0.12, 0.80).  
 
Conclusions: Drug-related activities provided the strongest cues for drug use, 
while craving was associated with more stable environments.  Interactive mHealth 
methods are capable of describing the drug-using environment and can provide the 
framework for developing context-sensitive interventions to support cessation and 
prevent relapse. 
Key words: substance use, mHealth, and ecological momentary assessment 
Introduction 
 
Substance abuse is a chronic disease often characterized by multiple attempts at 
abstinence with frequent relapse. It is associated with a range of morbidities as 
well as deleterious effects on family members and larger society [1-4].  
 
Capturing drug use in epidemiologic studies involves substantial recall bias [5, 6] 
and often does not quantify the amount or duration of use.  Drug use is often self-
reported (occasionally verified through biological measures) and typically captures 
any drug use over long periods of recall (e.g., 6 to 12 months) [7-9]. This broad 
time frame often misses varying periods of intense or intermittent use and further 
fails to capture the proximate context of an individual’s drug using experience. 
Drug-using behavior occurs within a specific organizational and structural 
environment with outcomes fundamentally linked to both individual and 
situational and factors [10]. Substance abuse is commonly associated with a 
chaotic or disordered life, mental illness, financial and legal difficulties, and 
inadequate housing or transportation [11-13]. Daily environmental cues of drug 
use remain largely unexamined as risk factors for drug use and barriers to care.   
 
Drug craving has been theorized to have a critical role in drug dependence and 
relapse, although there have been substantial inconsistences in data supporting this 
view [14, 15]. There is clear recognition of the need for more detailed and novel 
methods for measuring craving (e.g., a virtual reality approach to examine cue 
elicited tobacco cravings [16]).   
 
Ecological momentary assessment (EMA) methods collect participant-level data in 
real time and facilitate responsive communication between providers and patients. 
EMA is a mobile health (mHealth) method that employs mobile devices (e.g., 
smartphones or other hand-held devices) to improve health outcomes, healthcare 
services and public health research. These EMA methods have been utilized in 
smoking cession studies [17-23] and among methadone-maintained outpatient 
drug users [24-28]. EMA provides an ideal method for assessing drug craving by 
capturing transient ‘states’ rather than summing craving events over time to assess 
‘traits’.   By collecting real-time data, a more vibrant and comprehensible 
understanding of the drug-using environment can be generated. Knowing the 
proximate determinants of drug use and how they differ from drug craving and 
relapse can inform why some persons are able to maintain cessation while others 
are not. The current study utilizes EMA methods to ascertain the social, physical, 
activity and psychosocial environment associated with drug use compared to drug 




 EXACT study participants 
Exposure Assessment in Current Time (EXACT) study participants were recruited 
from the AIDS Linked to the IntraVenous Experience (ALIVE) study, an on-
going, community-recruited, observational cohort of persons with a history of 
injecting drugs in Baltimore, MD [29]. The ALIVE cohort is community- rather 
than clinic-based, thereby avoiding selection bias toward persons seeking or 
accessing care. Details of the EXACT study have been previously described [30], 
and included four successive trials conducted from November 2008 through May 
2013. Each trial was planned to follow 30 participants each for 30 days.  
 
Eligibility criteria for the EXACT study included current enrollment in ALIVE 
and the ability to understand and follow directions on a personal digital assistant 
(PDA) or mobile phone.  Individuals were excluded if they had any medical 
conditions that would prevent them from operating the hand held device (e.g., 
vision or hearing impairment) or failed to attend the screening appointment where 
they were trained on device use.  
 
In each trial, the specific inclusion criteria regarding drug use and HIV status were 
varied slightly to ensure a diverse sample; both injection and non-injection drug 
users were included.  In Trial 1, selection was made to balance the numbers of 
participants that reported heroin or cocaine use within the past month (defined as 
recent drug use) with those that were not currently using drugs. In Trial 2, all 
participants reported heroin or cocaine use within the prior three months. While 
HIV status was not a recruitment criterion in the first two trials, Trial 3 included 
only HIV-infected participants with recent heroin and cocaine use. These same 
criteria were also used in Trial 4, but the data collection was transitioned from a 
PDA to a smartphone platform [30].  
The Johns Hopkins School of Public Health Institutional Review Board approved 
the study protocol. All participants provided written informed consent. 
Participants were informed that involvement (or non-involvement) in EXACT 
would in no way affect their participation in ALIVE. 
Data Collection 
Hand-held devices delivered four prompts to complete surveys at random times 
daily between 8am and 9pm (known as random-prompt entries), and one end-of-
day (around 9 pm) survey for 30 days of observation. Participants were also asked 
to self-initiate a survey and self-report each time they either craved (but refrained 
from using) or used heroin or cocaine (or both) in any manner (smoked, snorted or 
injected); these responses represent event-contingent entries. Heroin only and 
cocaine only reports incorporated all reports of heroin or cocaine use (including 
those jointly with another drug).   
For each event, participants answered questions concerning their drug use, current 
mood, social, physical and activity environment, using survey instruments adapted 
from previous EMA studies [24-28].   Participants had 30 minutes to complete an 
event-contingent survey to ensure responses were recorded in real-time. All data 
used in the present analyses are from event-contingent entries.  
 
For Trials 1-3, participants were provided personal digital assistants (PDA, Palm 
Z22, Palm, Inc., Sunnyvale, CA, USA) running applications developed using 
Satellite Forms software (http://www.satelliteforms.net/). All PDA programs were 
disabled except for study-required applications. In Trial 4, participants were 
provided an Android Smartphone (Motorola Droid X2), running an application 
developed using the Electronic Mobile Open-source Comprehensive Health 
Application (eMOCHA) platform, created at Johns Hopkins School of Medicine. 
Previously, eMOCHA was used to support community health workers in resource-
limited settings heavily impacted by HIV [31].   
 
Baseline characteristics were obtained from audio-computer assisted self- 
interviews (ACASI) completed at enrollment into EXACT and/or from the prior 
ALIVE study visit. In addition to sociodemographic variables (e.g., age, sex, race, 
education, marital status, employment, income, homelessness and health insurance 
status), baseline data collection included self-reported alcohol, tobacco and illicit 
drug use [Drug Abuse Screening Test (DAST)] and depressive symptoms [Center 
for Epidemiologic Studies- Depression Scale (CES-D)] in the prior six-months 
[32].  
 
To reduce participant burden, event-contingent time-varying questions required 
only a “yes /no” response. These EMA variables included:  
Social environment: Whom participant was with during an event:  friend, 
acquaintance, family member, a stranger, a spouse, and a child, alone, 
someone currently using drugs or an “out-the-door partner” (someone a 
drug user visits for the purpose of using or buying drugs). 
 
Activity environment: What activity was participant engaged in when they 
reported an event: socializing, sleeping, eating, shopping, 
planning/thinking, engaging in recreational activities, drinking alcohol, 
using tobacco, offered drugs, saw or were with someone using drugs, saw 
drug paraphernalia, handling $10 in cash, engaging in illegal activity, or 
“copping” (exchanging small goods or services for obtaining drugs). 
 
Physical environment: Participant’s physical location when reporting an 
event: home, another’s home, car, bus or train, outdoors, church, 
job/working, restaurant, abandoned space, doctor’s office, store, shelter, 
bar, or “cop” spot (where someone goes to buy drugs).  
 
Psychosocial environment: Participant’s mood or motivation when 
reporting an event. Responses to the question, “How do you feel right 
now?” included “happy”, “stressed”, “tired”, “relaxed”, “bored”, “irritated” 
and “none of the above”. Responses were not mutually exclusive, allowing 
participants to mark all that applied. Motivational variables included 
responses to whether participants “wanted to see what would happen if you 
took just one hit” or “wanted to use out of the blue”. 
 Analysis 
This analysis examined the event-contingent entries using logistic regression 
models with generalized estimating equations (GEE) and autoregressive 
covariance structures to model the outcome of drug use vs. drug craving events 
(SAS Proc Genmod). GEE adjusted for the correlation of repeated measures 
within each subject over the 30-day period of follow-up. Variables selected for the 
final models of drug use vs. drug craving were chosen through step-wise 
regression. First, separate univariate models were run for each of the variables in 
the baseline characteristics, social, physical and activity environment and 
psychosocial variable categories.  
 
Variables with p-values<0.1 in univariate analyses were included in separate 
adjusted models for each of the different variable groups. Fully adjusted models 
for drug use and those stratified by heroin (i.e., heroin use vs. heroin craving) and 
cocaine use (i.e., cocaine use vs. cocaine craving) were generated to include all 
variables with p-values<0.1 from any of the adjusted group models. Final models 
for drug use, including heroin and cocaine use, were built to achieve parsimony 
and included statistically significant (p-value<0.05) variables from the fully 
adjusted models. All models included a control term for the number of records that 
each participant contributed to the dataset. An HIV stratified analysis was repeated 
using the same methods.  All analyses were conducted using SAS 9.3 (SAS 




Table 4.1 describes baseline characteristics for the 109 EXACT participants. The 
median age was 48.5 years (interquartile range (IQR) 43-53 years), 90% were 
African American, 52% male and 59% were HIV infected. At baseline, 23% of 
participants reported recent methadone treatment and 83% reported smoking 
cigarettes daily in the six-months prior to baseline assessment. A total of 2,798 
events were reported; 1,954 (69.8%) were drug craving and 844 (30.2%) were 
drug use events. Of the drug use events, 351 events were exclusively heroin 
(41.6%), 289 events were exclusively cocaine (34.2%) and 201 events were 
reports of using both heroin and cocaine (23.8%). Over the 30 days, the median 
number of self-reported craving events was 8 (IQR 5-14) and the median number 
of self-reported drug using events was 4 (IQR 1-10). 
 
Table 4.2 presents multivariable models A-E for the three outcomes of: drug use 
(n=844) vs. crave (n=1,954), heroin use (n=552) vs. heroin crave (n=1,284) and 
cocaine use (n=490) vs. cocaine crave (n=926). Each model describes odds ratios 
adjusted (aOR) for baseline characteristics, social, physical, activity and 
psychosocial environment variables. Variables included in these multivariable 
models were those that were significant in univariate analyses with p-value≤0.1. 
 
Among baseline factors (Table 4.2, Model A), participants with recent methadone 
treatment reported 27% of events as drug using and 73% as drug-craving events.  
In multivariable analyses, older age and recent methadone use were significantly 
associated with decreased odds of drug use (Table 2, Model A). Baseline reports 
of substance use included cigarette, heroin and cocaine use and all increased the 
odds of drug use over craving by 2-3-fold.  
 
Social environment factors (Table 4.2, Model B), including children being present, 
reduced the odds of using drugs while being around someone else using drugs 
increased the risk for using. Children were present at 11.5% of drug use events and 
88.5% of craving events.  Specifically, cocaine use increased significantly if 
participants reported being with an out-the-door- partner, if their spouse was 
present at the time of the event, or if someone had offered them drugs.   
 
With respect to the activity environment (Table 4.2, Model C), reports of eating 
around the time of the event were associated with reduced drug use. The 
likelihood of drug use increased with reports of using tobacco, handling $10 in 
cash and seeing drug paraphernalia. Tobacco use was reported at 92% of drug 
using events. Events where seeing drug paraphernalia was reported, 48% were 
drug-using events and 52% were drug-craving events. 
 
Physical environments (Table 4.2, Model D) that were associated with a reduced 
likelihood of using drugs included reports of being in a car, bus or train, at the 
doctor’s office, or at work. Reports of being at home, walking or wandering and 
being in an abandoned space at the time of the reported event were associated with 
increased odds of drug use. More drug use than drug craving events occurred in 
abandoned spaces (81% were drug use events, 19% were drug craving events).  
 
Regarding participants’ psychosocial environment around the time of the event 
(Table 4.2, Model E), reports of anger were associated with reduced drug use, 
while persons reporting being in pain because they needed a hit were 5-times as 
likely to use rather than crave drugs, especially with heroin use.   
 
Figures 4.1-4.3 depict the final multivariable models combining significant 
variables from these prior models for: any drug use (Figure 4.1), heroin only 
(Figure 4.2) and cocaine only (Figure 4.3). For any drug (Figure 4.1), drug use 
was significantly reduced with reports of being with a child (aOR 0.26, 95% CI: 
0.12,0.59), at the doctor’s office (aOR 0.31, 95% CI: 0.12,0.80) or eating (aOR 
0.54, 95% CI:0. 34,0.85) at the time of the event. Recent methadone treatment was 
marginally associated with reduced drug use  (aOR 0.57, 95%CI:0. 30,1.07). 
Factors associated with an increased likelihood of drug use included a 2-fold 
increase with recent heroin use (aOR 2.49, 95% CI: 1.34,4.61), a 3-fold increase 
with seeing drug paraphernalia (aOR 3.07, 96% CI: 1.97,4.80) and a 6-fold 
increase with being in an abandoned space at the time of the event (aOR 6.65, 
95% CI: 1.78, 24.84). Additional predictors of any drug use in the final adjusted 
model included: using tobacco at the time of the reported event (aOR 2.27, 
95%CI: 1.37,3.78), handling $10 in cash (aOR 1.70, 95% CI: 1.11,2.59), being 
with someone who was using drugs (aOR 1.45, 95% CI: 1.13,1.86), being with 
your spouse (aOR 2.09, 95% CI: 1.22,3.59), being a home (aOR 1.68, 95% CI: 
1.00,2.82) and walking/wandering (aOR 1.68, 95% CI: 1.11,2.54) at the time of 
the event.  
 
While there was some overlap between the overall final models for any drug use, 
heroin only and cocaine only (e.g., protective associations with being around 
children or doctors office, increased risk with seeing drug paraphernalia; Figures 
4.1- 4.3), there were several factors uniquely associated with the type of drug 
used.  For heroin use events, as might be expected, reports of heroin use in the 
period just before study entry increased use risk, while recent methadone treatment 
reduced risk. There were specific demographic differences as well. African 
Americans were less likely than Caucasians to use heroin (aOR 0.47, 95% CI: 
0.19,0.15), while older adults (≥50 years of age) were less likely to use cocaine 
(aOR 0.39, 95% CI: 0.22,0.68). In addition to increased risk associated with 
activities like walking and wandering and seeing others use drugs, tobacco use 
was strongly associated with heroin use, including both recent intensity of 
smoking prior to study entry and cigarette smoking concurrent with the event.  In 
contrast, social context appeared uniquely associated with increased likelihood of 
cocaine use, including being in the presence of others using drugs, a spouse, or an 
“out-the-door” partner (aOR 7.90, 95% CI: 1.45,43.01).  After accounting for 
other sociodemographic and environmental factors, psychosocial factors were not 
significantly associated with drug use overall or with using heroin or cocaine only.  
 
A restricted analysis of HIV infected individuals revealed that being with a child 
and recent methadone treatment were predictors of drug craving whereas using 
tobacco, handling $10 cash, seeing someone use and past heroin use were 
predictors of drug use. The point estimates (not shown) were similar to those in 
the final drug use vs. craving model in Figure 4.1. Additional sensitivity analyses 
restricting heroin and cocaine use to exclusively heroin or cocaine (excluding 
reports of mixed heroin/cocaine use events) resulted in similar estimates as the 




This ecological momentary assessment study provides real-time data to 
characterize the social, physical and activity environment of drug users where and 
when it actually occurs. Among 109 participants followed for a 30-day period, we 
demonstrated distinct drug using and drug craving environments.  Our data 
suggest that drug use is facilitated over craving in less structured social and 
physical environments. Further, the presence of drug-related activity appears often 
to serve as a catalyst for illicit drug use. Our study provides novel data that 
individual, social, and physical environmental factors during craving events may 
mitigate against drug use. These findings implicate the need to strongly consider 
proximate environmental factors in designing individualized interventions to 
reduce relapse to drug use.  
Less structured social and physical environments including reports of walking and 
wandering or being in an abandoned space at the time of an event were highly 
associated with drug use rather than drug craving. Physical environments where 
drug use may readily occur have been theorized to represent environments 
impacted by disadvantage and deprivation, lack structure and present drug 
exposure opportunities [33-35].  Practically, informal physical environments may 
give rise to drug use because individuals can wander without difficulty where drug 
sales are common, readily locate and access abandoned spaces and more easily 
evade law enforcement [36-38]. Abandoned buildings may help protect from 
police intrusion but importantly, will lack facilities to ensure clean injection 
equipment[39].  
Drug-related activities provided the strongest cues for drug use in this analysis. 
Activities including handling small amounts of cash, seeing drug paraphernalia or 
being around others using drugs were strongly associated with participants 
reporting drug use. These associations suggest use is intensely influenced by 
situational drug triggers, which may be difficult to avoid in some heavily impacted 
communities. These real-time EMA data are consistent with our prior reports from 
the ALIVE cohort that moving from a highly deprived neighborhood to a less 
deprived one is among the strongest predictors of maintaining long-term cessation 
[33]. Exposure to drug use, through individuals or paraphernalia not only indicates 
drug availability but also provides the opportunity to maintain their using habits. 
Reports of handling $10 in cash reflect the nature of our participants’ cash-based 
financial lives, however, the strong association with using drugs suggests it may 
also be a trigger for drug use. It has been previously reported that the likelihood of 
handling cash increases in the hours preceding cocaine use and although this may 
reflect transactions needed to buy cocaine, it could also indicate that handling cash 
triggers the temptation to use drugs [26].  
 
We also found that being at home or with a spouse was an environment where 
drug use easily facilitated. Although different from an abandoned space- a home is 
controlled by an owner or renter and is only accessible to acquaintances of the 
home. Using drugs at home with or without a spouse may represent a shared drug 
addiction where drug use is enabled [40]. These associations are likely to be 
bidirectional with individuals seeking certain settings when they plan to use and 
certain environmental factors facilitating use. 
 
Recent methadone treatment was associated with drug craving. An expected 
finding, methadone is effective treatment of opioid addiction and is a proven 
strategy to support heroin abstinence and to reduce injection-related risk behavior 
and other undesired social behaviors, such as criminal activity [41]. Conversely, 
self-reports of heroin use and cigarette smoking within the six months prior to the 
start of EXACT were predictors of using drugs and heroin. The prevalence of 
cigarette smoking among illicit drug users is among the highest reported from any 
population [42] and illicit drug users may experience stronger physiological 
dependence to nicotine as a result of their addiction [42-44].  Understanding the 
dynamics of tobacco and illicit drug use warrants further investigation, however, 
our analysis suggests a considerable need for combination therapy targeting both 
illicit drug use and smoking [45-47]. Timely integration of smoking cessation into 
drug treatment programs could potentially help support abstinence from illicit drug 
use while addressing the disproportionate burden of tobacco use in this population.  
 
Our analysis showed that drug craving without using occurred more frequently in 
structured physical and social environments. These situations included being with 
a child, at the doctor’s office, at work, eating or in formal transport such as a car, 
bus or train. Structured activities like having a job, eating regular meals, spending 
time with a child, and attending clinic appointments are likely indicators of a more 
stable lifestyle and suggest a more controlled environment with responsibilities for 
self-care and care for others.  
 
It has been suggested that craving and relapse may represent independent 
phenomena and that reports of craving may not predict relapse [48, 49].  However, 
it is possible that craving represents episodes where individuals have motivation to 
use but other environmental factors impeded use.  Building on this premise, our 
findings suggest that EMA may be utilized to tailor drug treatment interventions.  
By identifying social, physical and activity environments associated with craving 
and drug use, drug users could be counseled and supported to avoid such settings 
and to facilitate time in environments that reduce the probability of drug use.  
 
Although we demonstrate a clear distinction between the drug-using and drug-
craving environments, this analysis is limited to event monitoring and therefore 
can only generate information concerning drug use or craving events. With this 
event-focused analysis, it is not possible for example, to distinguish between 
subjects who spend regular amounts of time with other drug users from subjects 
who are only around drug users when they choose to use.  
 
As previously reported, the EXACT study demonstrated the ability to efficiently 
and effectively collect high-quality, real-time EMA data in a challenging study 
population of drug users [30]. In this study, we provide evidence that EMA 
methods represent a novel interactive mHealth strategy for capturing the drug 
using experience in natural settings. The next step for these methods is to move 
beyond real-time data collection towards tailored interventions in response to these 
environmental cues. As our understanding of the drug-using environment 
improves, ecological momentary interventions (EMI), such as those that utilize 
GPS to alert and divert drug users when they approach a location that was 
previously a spot for drug use, or the delivery of motivational or cognitive 
behavioral therapies in real-time as personalized, context-sensitive interventions, 
hold great promise to improve drug treatment and prevent drug relapse. 
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* All baseline characteristics represent behavior within the 6 months prior to the start of EXACT 
 Recent drug use was part of the inclusion criteria for Field Trials 3 & 4. Drug use includes any route of 
administration (smoking, snorting, and injecting). 
 HIV+ status was part of the inclusion criteria for Field Trials 3 & 4. 
+ CD4 & viral load based on HIV-infected participants only. 
  
Characteristic N % 
Median Age, IQR 48.5 (43-53) - 
Male 58 52 
African American 98 90 
Never Married 66 61 
High School Education 44 40 
Alcohol use  71 65 
CES-D>23 26 23 
Cigarette use  91 83 
<1/2 pack cigarettes per day 20 18 
>1/2 pack cigarettes per day 71 65 
Income<$5,000 83 77 
Homeless 9 8 
Medical Insurance 93 85 
Have a primary care doctor 97 89 
Drug abuse, DAST>16 6 18 
Methadone Treatment  26 23 
Marijuana use  27 24 
Speedball use* 26 23 
Heroin use (any route) Δ 52 46 
Cocaine use (any route) Δ 54 47 
Hepatitis C positive 94 86 
HIV positive++ 64 59 
     Median CD4(IQR)+ 360.5(239-529) - 
     Viral Load>500+ 35 55 
• All baseline characteristics represent behavior within the 6 months prior to the start of EXACT 
• Bold values indicate p-value<0.1 
• All models are adjusted for variables with listed values 
• Empty cells represent variables not included in multivariable models as they were not statistically significant (p<0.1) in univariate analyses 
 Table 4.2: Multivariable adjusted odds ratios of drug, heroin and cocaine use vs. crave 
  Drug Use vs. Drug crave Heroin use vs. Heroin crave Cocaine use vs. Cocaine crave 
MODEL A: BASELINE 
CHARACTERISTICS aOR 95% CI P-value aOR 95 % CI P-value aOR 95 % CI P-value 
Female 1.51 0.84 2.72 0.173 
Age≥50 0.55 0.29 1.04 0.0652 0.42 0.22 0.81 0.0089 
Black 0.85 0.34 2.12 0.7279 0.55 0.28 1.08 0.0808 
HS Education 0.68 0.41 1.14 0.1435 0.97 0.6 1.56 0.8876 0.84 0.48 1.47 0.5457 
Ever Married 0.74 0.43 1.29 0.2921 0.72 0.37 1.39 0.3236 
# Packs/day of Cigarettes  
0 Ref Ref Ref Ref Ref Ref Ref Ref 
<1/2 pack/day 2.06 0.66 6.4 0.2112 3.77 1.46 9.73 0.0061 
>1/2 pack/day 1.2 0.35 4.15 0.7686 1.11 0.38 3.22 0.8476 
CESD≥23 0.95 0.38 2.37 0.9128 
Methadone treatment  0.3 0.18 0.51 <0.0001 0.33 0.15 0.71 0.0043 
Any heroin 3.4 1.59 7.3 0.0017 3.48 1.44 8.4 0.0055 2.51 1.07 5.88 0.0337 
Any cocaine 2.21 1.28 3.81 0.0043 1.59 0.81 3.11 0.1745 2.67 1.37 5.21 0.004 
Any Speedball  0.77 0.4 1.47 0.4268 0.88 0.4 1.94 0.7459 
  Drug Use vs. Drug crave Heroin use vs. Heroin crave Cocaine use vs. Cocaine crave 
MODEL B: SOCIAL 
ENVIRONMENT aOR 95% CI P-value aOR 95 % CI P-value aOR 95 % CI P-value 
With an Acquaintance 
Alone 
With family 0.63 0.33 1.21 0.165 
With a child 0.25 0.14 0.43 <0.0001 0.17 0.08 0.4 <0.0001 0.31 0.16 0.59 0.0004 
With a friend 1.06 0.76 1.48 0.7322 1.09 0.77 1.56 0.6157 
With an out-the-door partner 2.28 0.81 6.42 0.1174 6.69 1.38 32.4 0.0182 
With your spouse 1.78 1.09 2.92 0.0218 2.11 1.26 3.53 0.0044 
With a stranger 
Were offered drugs 1.74 0.98 3.1 0.0607 1.43 0.76 2.67 0.263 2.09 1.13 3.86 0.0182 
With someone who is using 2.52 1.78 3.57 <0.0001 2.51 1.53 4.13 0.0003 2.65 1.8 3.92 <0.0001 
Table 4.2: Continued 
Drug Use vs. Drug crave Heroin use vs. Heroin crave Cocaine use vs. Cocaine crave 
MODEL C: ACTIVITY 
ENVIORNMENT aOR 95% CI P-value aOR 95 % CI P-value aOR 95 % CI P-value 
Eating 0.6 0.43 0.84 0.0027 0.55 0.36 0.84 0.0059 
Planning 0.99 0.61 1.61 0.9819 1.04 0.61 1.76 0.8852 0.96 0.59 1.54 0.8509 
Handled $10 in cash 1.54 1.06 2.24 0.0242 1.56 0.98 2.5 0.0625 1.47 0.89 2.43 0.1317 
Copping 1.72 0.99 3.00 0.0548 1.29 0.62 2.69 0.4905 1.73 0.71 4.21 0.2279 
Saw someone use 1.17 0.74 1.83 0.5087 1.55 1.04 2.31 0.0312 2.33 1.33 4.07 0.003 
Saw drug paraphernalia 3.56 1.91 6.63 <0.0001 4.2 2.21 7.97 <0.0001 2.27 1.24 4.12 0.0074 
Socializing 0.97 0.66 1.42 0.8828 0.87 0.63 1.22 0.4273 0.97 0.6 1.58 0.9076 
Using tobacco 2.44 1.51 3.96 0.0003 3.19 1.51 6.76 0.0024 1.84 1.07 3.16 0.028 
Sleeping 0.96 0.65 1.41 0.8254 0.77 0.44 1.37 0.3745 
Doing illegal activities 0.81 0.29 2.23 0.681 1.08 0.39 3.04 0.8796 
Drug Use vs. Drug crave Heroin use vs. Heroin crave Cocaine use vs. Cocaine crave 
MODEL D: PHYSICAL 
ENVIRONMENT aOR 95% CI P-value aOR 95 % CI P-value aOR 95 % CI P-value 
At your home 1.83 1.13 2.97 0.0137 1.81 1.11 2.95 0.017 
In a car/bus/train 0.32 0.15 0.68 0.0029 0.34 0.18 0.64 0.0008 0.25 0.1 0.6 0.0018 
At the doctor’s office 0.19 0.06 0.62 0.0061 0.16 0.04 0.61 0.0078 0.16 0.05 0.51 0.002 
At a restaurant 3.78 1.04 13.82 0.044 8.5 3.26 22.2 <0.0001 2.07 0.42 10.34 0.3739 
At your work place 0.34 0.18 0.66 0.0012 0.53 0.23 1.24 0.1452 0.55 0.21 1.44 0.2211 
At a store 0.38 0.18 0.79 0.0092 0.33 0.14 0.75 0.0084 
Wandering/walking 2.78 1.84 4.21 <0.0001 3.31 2.17 5.05 <0.0001 2.04 1.34 3.11 0.0009 
In an abandoned space 7.94 3.64 17.31 <0.0001 4.44 1.77 11.19 0.0015 7.52 3.44 16.42 <0.0001 
Drug Use vs. Drug crave Heroin use vs. Heroin crave Cocaine use vs. Cocaine crave 
MODEL E: PYSCHOSOCIAL 
ENVIRONMENT aOR 95% CI P-value aOR 95 % CI P-value aOR 95 % CI P-value 
You were angry 0.41 0.2 0.87 0.0196 0.47 0.18 1.2 0.115 
You were in pain because you 
needed a hit 5.17 2.21 12.05 <0.0001 8.94 4.07 19.62 <0.0001 2.80 1.05 7.45 0.0388 
Wanted to see what would happen 
if you took one hit 0.81 0.45 1.46 0.4767 
Wanted to use out of the blue 1.42 0.65 3.11 0.375 0.79 0.34 1.85 0.5839 3.12 0.82 11.83 0.0944 
• All models are adjusted for variables with listed values and bold values indicate p-value<0.1
Empty cells represent variables not included in multivariable models, as they were not statistically significant (p<0.1) in univariate analyses
 
Figure 4.1: Odds ratio of drug use vs. drug cravinga 
 
Figure 4.1: Drug use refers to any drug use reported in real-time and is defined as the use of heroin or 
cocaine, in any manner, over the 30-day EXACT study period. 
a Model adjusted for all variables listed
 
Figure 4.2: Odds ratio of heroin use vs. heroin cravinga 
 
Figure 4.2: Heroin use refers to all uses of heroin reported in real-time including those jointly with another 
drug, in any manner, over the 30-day EXACT study period. 
* Cigarette packs/day was assessed at baseline represents use within the 6-months prior to the start of 
EXACT  
a Model adjusted for all variables listed  
 
Figure 4.3: Odds ratio of cocaine use vs. cocaine cravinga 
Figure 4.3: Cocaine use refers to all uses of cocaine reported in real-time including those jointly with 
another drug, in any manner, over the 30-day EXACT study period. 
a Model adjusted for all variables listed
Chapter 5:  
Conclusions and Future Directions 
 
Summary of Results 
Illicit drug users are a known challenging population to research. Identifying, 
recruiting and retaining drug users is problematic in epidemiologic, behavioral and 
clinical research studies. Additionally, individuals with substance abuse problems 
tend to have a range of vulnerabilities that place them at increased risk for relapse 
as well as becoming HIV infected and failing to achieve desired treatment 
outcomes of viral suppression [1, 2]. The motivation behind this dissertation 
stemmed from the need for novel methods to understand illicit drug users and the 
context of the drug-using environment to improve health outcomes among this 
high-risk population.  
The Exposure Assessment in Current Time study was the first ecological 
momentary assessment (EMA) study to examine the drug-using environment 
among community-dwelling, out-of-treatment drug users, utilizing hand-held 
mobile devices. This dissertation examined how mHealth methods can capture and 
quantify self-reported drug use, described the heterogeneous patterns of drug use 
and their associations with engagement in care, as well as demonstrated the role of 
contextual factors in determining drug using risk behavior.  
Chapter 2 examined the concordance and inter-rater reliability of ecological 
momentary assessment methods compared to well understood and validated 
methods of audio computer-assisted self-interview (ACASI) and biological sweat 
patches for assessing drug use [3-6]. Table 5.1 summarizes the different features 
of each method and how they each capture drug use. Our analyses demonstrated 
that EMA methods have strong concordance for both biological sweat patch and 
ACASI-based methods for capturing heroin and cocaine use. The overall percent 
agreement between EMA and sweat patch methods for cocaine use was 70%, 
while the overall percent agreement between EMA and ACASI methods for 
cocaine use was 77%. The percent agreement between EMA and sweat patch 
methods for heroin was 72%, while the overall percent agreement between EMA 
and ACASI methods for heroin use was 79%.  
 The kappa statistic is a measure of inter-rater reliability that takes into account the 
agreement occurring by chance. The kappa statistics were slightly lower for 
comparisons of drug use between EMA and sweat patch methods than for EMA 
and ACASI methods. The kappa statistics for the comparison of EMA and sweat 
patch methods were in the moderate agreement range for both cocaine 0.51 (0.44-
0.60) and heroin 0.48 (0.38-0.57) use. The agreement in reports between EMA and 
ACASI methods for cocaine use was 0.59 (0.51-0.67) and heroin use 0.61 (0.53-
0.69), which represents moderate and good agreement respectively. 
Our comparisons of mHealth methods with biological samples of sweat were 
concordant (as demonstrated by high percent agreement with EMA) but had lower 
inter-rater reliability than we would have predicted. The unexpectedly lower 
number of patches that tested positive for heroin, but not cocaine, suggested a 
possible misclassification of heroin use by the gold standard.  
The level of concordance between EMA and more traditional biological and self-
report methods suggests that utilizing EMA mHealth strategies are feasible for 
assessing drug use among community dwelling, non-treatment seeking chronic 
drug users. Further, EMA methods remain more flexible and less invasive than 
drug testing that involves blood, sweet or urine. Additional strengths of EMA 
methods include their ability to capture both exposure and outcome information in 
real-time rather than waiting months to be assessed at the next study visit, as well 
as the ability for data collection to be completed in participant’s natural 
environment rather than in a formal clinic setting.  Assessment of drug use by 
mHealth methods is particularly compelling when considering the strengths, costs 
and burdens associated with assessing illicit drug use.  
In chapter 3, growth mixture models (GMM) were utilized to examine the 
heterogeneous patterns of daily drug use among participants in EXACT. This 
analysis examined total drug use on a daily basis rather than on a weekly basis, as 
was done in chapter 2. Examining daily drug use through GMM found substantial 
variability in drug using risk among the EXACT population, as evidenced by three 
distinct groups of drug users; low, moderate and high intensity drug users. These 
three drug using risk groups represented individuals with increasing intensity of 
heroin or cocaine use and whose membership characteristics were distinct. 
Compared to those in the low intensity drug using group, those classified as high 
intensity drug users were younger, less likely to be HIV infected and more likely 
to share needles and use a variety of drugs including injecting heroin and cocaine 
separately, together (as speedball) and smoking crack. The high frequency of poly-
drug use and needle sharing behaviors of the high intensity drug using group is not 
only associated with longer time to cessation [7] but puts individuals at risk for the 
medical consequences of continued drug abuse as well as HIV transmission,  
acquisition and  poor HIV treatment outcomes [8].  The paradoxical reduced HIV 
prevalence among high intensity users may represent a cohort effect of younger 
more intense users with distinct social networks from older users [9] who, by 
nature of declining HIV prevalence have been spared (for now) from acquiring 
HIV. 
 
The groups discovered through growth mixture modeling had clinical relevance as 
well. Those classified as high intensity users were found to also be individuals 
who were likely to fail to attend outpatient medical appointments and were less 
likely to have health insurance at the visit following the completion of the EXACT 
study. Participants were not engaging in care possibly because they were currently 
out of medical care.  
Chapter 4 examined the drug-using environment by studying each EMA drug 
using and craving event for every individual. Our refined assessment of the 
context of drug use demonstrated that drug use and craving are possibly distinct 
experiences represented by different social, physical and activity environments. 
We demonstrated that drug use was facilitated over craving in less structured 
social and physical environments, such as being in an abandoned space or being 
around others engaging in drug-related activity. Whereas drug craving without 
using occurred more frequently in structured physical and social environments, 
including being with a child, at the doctor’s office, or at work.  
It has been suggested that craving and relapse may represent independent 
phenomena and that reports of craving may not predict relapse [10, 11].  However, 
it is possible that craving represents episodes where individuals have motivation to 
use but other environmental factors impeded use. Our findings suggest there are 
different associated factors of craving vs. use but more research is needed to 
provide evidence that they are distinct entities. Craving in specific environments 
could lead to use but it is context specific.  Building on this premise, our findings 
suggest that EMA may be utilized to tailor drug treatment interventions.  By 
identifying social, physical and activity environments associated with craving and 
drug use, drug users could be counseled and supported to avoid such settings and 
to facilitate time in environments that reduce the probability of drug use.  
Lessons Learned 
 
This body of work adds to a growing evidence base that suggests ecological 
momentary assessment methods are appropriate for assessing challenging and 
marginalized populations. These EMA data provide extremely valuable 
information on the proximate influences of drug users’ behavior as well as 
demonstrate the richness of information gained from shortening the data collection 
interval to minutes instead of months and of locating data collection to occur 
wherever persons may be, rather than relying on retrospective reporting in a clinic 
setting. Allowing questions to be responded to in ones’ personal environment 
affords participants the opportunity to answer open and honestly and could 
increase the integrity of the data collected. 
 
Implementing the EXACT study was met with skepticism regarding the likelihood 
of success in meeting our objectives of understanding the drug-using environment. 
We did require a substantial amount of effort from participants in reporting each 
drug use or craving event and in responding to 5-random prompt surveys a day (a 
slightly higher participant burden than many EMA studies). Overall, EXACT 
participants answered 78% of random-prompts, a response rate comparable to 
other EMA studies performed using similar technologies in varied settings [12, 
13]. Studies among populations of illicit drug users, chronic pain patients, 
smoking cessation and obesity intervention participants all achieved EMA 
response rates to random-prompt surveys ranging from 70–80% [12, 14-16].  User 
fatigue, or exhaustion to responding to device prompts, was another concern of 
using EMA methods.  To examine this potential issue in EXACT, both the 
percentage of random-prompts answered and the daily mean numbers of responses 
answered were examined by study week. We found no difference in either the 
response proportion or average number of daily responses between study weeks 
[17], suggesting fatigue was not a problem for our participants. 
Informal debriefs of participants’ experiences in EXACT at the conclusion of the 
study demonstrated that participants believed study procedures were not overly 
burdensome or hard to understand. Although we did not conduct formal qualitative 
evaluations, these debriefs were consistent with our quantitative assessment of 
participant acceptability, indicating that participants were not over burdened by 
study procedures or their participation [17]. 
A concern in using technology for public health research is the rapid evolution and 
out-datedness of mobile devices. In the EXACT study, the PDA model we used at 
study initiation was no longer manufactured after 10 months of study recruitment 
and was largely obsolete by the end of the study. Rapid developments in 
technology may become a significant barrier to successful implantation and scale-
up of mHealth programs in the future.  In EXACT, the switch to Android 
smartphones and the eMOCHA platform resulted in more efficient delivery of 
prompts and automatic data transfer (with the use of cellular data plans), which 
both enhanced security and minimized data loss. To better address the rapid 
changes in technology, alternative approaches to study design must be considered, 
including designs fitted to the stage of technology or intervention development, 
adaptive trials and Continuous Evaluation of Evolving Interventions (CEEI) that 
allow for technology or intervention optimization [18, 19].  
An abundance of public health information concerning the drug-using 
environment, heroin and cocaine use, drug craving, as well as insights into 
mHealth methods were gained from completing the EXACT study. Following 
through on this wealth of information must include utilizing these methods for 
intervention and prevention programs aimed at addressing drug relapse as well as 
uptake of engagement in care practices.  
 
Future Directions 
This dissertation employed EMA methods to develop a comprehensive 
understanding of the drug-using environment among out-of-treatment drug users.  
Specifically, we uncovered non-uniformity in the drug using intensity and risk 
among this population of illicit drug users. Although not part of traditional clinical 
practice, physicians could begin to routinely ask about a patient’s drug use 
intensity on a daily basis. This question in conjunction with questions concerning 
drug use history, current mood, and social, physical and activity environments 
would provide clinicians with a deeper understanding of the drug using patterns of 
their patients, help in predicting relapse as well as the likelihood of ART 
adherence among HIV infected drug users. Long-term clinical goals of this work 
include incorporating EMA data directly into electronic medical records (EHR).  
The EXACT study provided a deeper understanding of the proximate influences of 
drug use, which could allow for tailored interventions. Ecological Momentary 
Interventions (EMI), are interventions provided in real-time and are carried out in 
participant’s natural environments with the goal of real-time behavior change.  
EMIs are delivered in many forms using features of mobile devices including text 
messaging, photographs and videos. Interventions can be delivered to participant’s 
phones as unstructured passive clinical recommendations throughout the day (e.g., 
breathing techniques for individuals who suffer from anxiety [20] or promoting 
physical activity for underactive adults [21]). These interventions remind 
individuals of useful techniques for handling daily health matters as well as 
provide them with tools to achieve healthier lifestyles.  Structured interventions 
may include formalized clinical advice for patients with specific medical needs at 
critical times (e.g., participants in smoking cessation programs receiving text 
messages with tips for dealing with cravings during periods when smoking is often 
reported [22]). These structured interventions are informed by the patterns and 
timing of individual behaviors that have been previously uncovered from EMA 
analyses [23]. Although many studies have shown treatment gains immediately or 
shortly after the intervention, there remains conflicting evidence regarding the 
maintenance of effects when using text messages alone for the intervention. 
Furthermore, these passive interventions may not be suitable for high-risk 
populations. 
Newer forms of ecological momentary interventions involve the use of location-
based technologies embedded in all smart phones. Geographical positioning 
systems (GPS), altimeters and pedometers are now routinely incorporated into 
smart phones. These time stamped features have begun changing how 
interventions are delivered and will continue to evolve as our understanding of 
human moment grows.  Our understanding of the real-time drug-using 
environment must be updated to include how time and space play a role in drug 
use and craving and how individuals experience fluctuating exposures within a 
single day and within varying environments. Ecological momentary interventions 
that are associated with GPS movements as well as time of day, day of week and 
time of month of drug use and craving must still occur in natural environments at 
identified moments in everyday life, allowing EMI to provide real-time support in 
the real world.  
For example, it is well understood that substance abuse is a disease marked by 
frequent relapse and for most, a life-long struggle. Whether an individual attended 
inpatient treatment or not, regular on-going check-ups to assess the severity of 
abuse is atypical after an overdose. This scarcity rises as marginalized 
disadvantaged communities struggle to access an already strained treatment 
system, face the cost of medical insurance and regular appointments necessary for 
on-going care. However, with the use of smart phones, treatment support and drug 
monitoring could be available almost constantly. Personalized care is possible at 
the moment of greatest need. Patients could be monitored passively and if they 
wander into an area where they previously reported using drugs their smartphone 
could ask why they are in that location, provide them an alternate route to walk or 
provide them emotional support for dealing with a drug craving in real-time.  
An example of this is an intervention that was recently completed in the 
Addiction-Comprehensive Health Enhancement Support System Study (A-
CHESS) [24]. A randomized clinical trial of patients leaving 3 Midwestern 
residential treatment programs for alcohol abuse provided participants in the 
intervention group with a smartphone with the A-CHESS application. The 
application had both a static component (audio-guided relaxation) and interactive 
features. For example, if a patient neared a high-risk location, such as a bar she 
used to frequent, the GPS system initiated an alert asking the patient if they 
wanted to be there. On a weekly basis, participants also completed a questionnaire 
related to risky drinking and if the risk score exceeded a certain threshold, A-
CHESS automatically sent notifications to counselors.  Results demonstrated that 
over the previous 30 days at 4, 8 and 12 months post residential treatment, those 
who received the A-CHESS application reported a lower mean number of risky 
drinking days and a higher likelihood of consistent abstinence than those who 
received treatment as usual. As one of the few health care applications tested 
rigorously, A-CHESS provides promising results for sustained patient behavior 
change for future studies involving substance-using populations.  
 
Additionally, continuation of EMA self-reports of drug use could allow clinical 
staff, nurses or trained peer navigators to monitor individuals’ drug use and 
craving. Peer navigators are typically individuals who have similar backgrounds 
and past experiences as those they are guiding, thereby providing access and 
credibility not easily achieved by medical professionals [25].  Previous studies 
have demonstrated the potential for peer-based interventions to increase adherence 
to medical care for active persons who inject drugs [26] and our group is currently 
working on a project entitled “Technology-Enhanced Peer Navigation to Improve 
Injection Drug Users Engagement in HIV Care” with the hopes of establishing the 
feasibility and acceptability for a novel mHealth intervention to improve 
adherence and retention in care for HIV-infected drug users. These trained 
individuals would monitor EMA responses and contact patients if there were 
drastic changes in drug using behavior (e.g., high spikes over a weekend) and help 
guide and counsel patients with their drug-related problems.  The two-way 
communication is the hallmark of ecological momentary assessments and 
interventions. These EMI methods would continue to allow patients to be under 
the care of a physician but with less cost and burden to the participant and a shift 
in treatment and care routinely provided by the physician compared to a mid-level 
provider or peer.  
Assessment of drug use in epidemiologic studies can be enhanced through 
mHealth strategies. Capturing drug use optimally will involve an approach that is 
unobtrusive, does not rely on recall, has limited requirements for participant 
participation, and that is readily accessible and affordable. Remote monitoring 
with wearable sensors is currently under evaluation to determine if sensors can 
identify the onset and duration of cocaine use. iMStrong (PI Edward Boyer, Univ 
of Massachusetts) is a system comprised of an unobtrusive, wearable sensors that 
continuously record and wirelessly transmit physiologic measures (e.g., increased 
electrodermal activity, skin temperature, and motion) of sympathetic nervous 
system arousal that works with a smartphone to alert individuals to the onset of 
drug cravings.  Similarly, “AutoSense” involves anunobtrusive, wearable sensor 
that can collect heart rate, respiration patterns and blood alcohol levels in the 
natural environment of any person who is wearing the sensor [27]. These methods 
for real-time quantification of alcohol and cocaine use could be adaptable to 
measuring other illicit substances in non-clinical settings.  
Figure 5.1 describes the framework for future directions of this work as well as a 
system that uses the contextual information gained from EMA combined with 
newer mHealth technologies. More detailed EMA data can be collected through 
the use of common features of a smart phone (photographs and videos) while geo-
tracking technologies (GPS monitoring and accelerometers) and biosensors worn 
on the body (real-time sensing of metabolites and physiology) would enhance our 
understanding of the drug using environment, gather more detailed data in real-
time and be used for interventions. 
 
Conclusions 
The field of mHealth remains largely stuck in the land of “apps on a phone” and 
generally lacks rigorous evaluation. Bringing mHealth interventions to scale 
requires initial feasibility studies, like the EXACT study, followed by larger trials 
to test the effectiveness of mHealth approaches to optimizing care. Ecological 
momentary assessment methods do hold promise for reaching and characterizing 
high-risk drug using populations, as several studies have demonstrated these 
populations are capable of utilizing mobile devices to repeatedly describe their 
behaviors.  
 
The uptake of mHealth methods and interventions holds even greater potential as 
more individuals receive insurance coverage due to the new Patient Protection and 
Affordability Act in the United States.  Ecological momentary assessments and 
interventions and sensors should become economically viable as more individuals 
become insured and potential offsets in the cost of smartphones and data plans are 
made available. The results of this dissertation underscore the benefits of changing 
how epidemiologic data can be collected and assessed in real-time, and 
demonstrate the ability of poly-drug using individuals to provide behavioral data 
in their daily life, allowing for a novel and more precise method for characterizing 
the drug using experience and designing tailored interventions to mitigate the 
consequences of drug use.  
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Method of drug use assessment 
Ecological Momentary Assessment (EMA) 
Audio Computer-Assisted Self-
Interview (ACASI) Sweat-Patch 
What device is used to capture 
drug use? 
Mobile Phone, Tablet or Hand-held device 
(e.g. Personal Digital Assistant)  Computer or Lap-top PharmChek® Sweat Patch 
How is drug use captured? 
Participants self-cue and self-report in real-
time through the device 
Participants are asked to recall 
drug use behaviors and self-report 
through the computer 
Participants wear the sweat patch and 
drug metabolites secreted in sweat are 
captured on the patch 
Is internet access necessary? 
Not necessarily; Responses can be stored on 
the device and transferred at study 
conclusion, OR responses can be pushed to a 
server if wireless internet is available 
No, data is captured and stored on 
a computer No 
How often do participants 
visit study site? 
For studies with short follow-up (e.g. less 
than 30 days) participants may only need to 
visit the study site to pick-up and drop off 
the device and responses to survey 
questionnaires are done in the participant’s 
natural environment. This depends on the 
other requirements of the study (e.g. if 
weekly biological samples are needed) 
ACASI interviews typically take 
place at study sites and are 
required as often as the study 
protocol requires. For example, for 
studies requiring semi annual 
follow-up, participants return to 
the study site twice a year to 
answer questions via ACASI. If 
the participant does not attend the 
study visit, the data is missing for 
that visit 
Sweat-patches can be worn for up to 10 
consecutive days. The sweat-patch 
captures drug metabolites for the duration 
of time the patch is worn. Participants 
must visit the study site for the patch to 
be put in place and removed. Depending 
on the study protocol, this could be as 
frequent as every 2-3 days.  
How long does assessment 
take? 
Participants self-initiating an event survey 
concerning the outcome of interest will also 
most likely answer questions concerning the 
context of the event, e.g. who were you with, 
what were you doing, what were you feeling. 
The EXACT survey took approximately 5 
mins. The same questions are asked each 
time a participant self-reports 
Because interviews are often 
spaced out over months, an ACASI 
survey will ask more questions that 
are over arching 
 The patch can be worn  
continuously for up to 10 days 
Table 5.1: Assessment of illicit drug use via Ecological Momentary Assessment, Audio Computer-Assisted Self- 
Interview and Sweat Patch 
Table 1: Assessment of illicit drug use via Ecological Momentary Assessment, Audio Computer-Assisted Self- Interview 
and Sweat Patch (cont.) 
Expense 
Cell-phones, airtime and data plans are 
necessary to collect EMA data. Prices vary by 
cellular carrier. Remuneration is also 
necessary for participation. The EXACT study 
cost approximately $427.33 per participant, or 
$15.29 per day of 30 days of follow-up (this 
price includes the GPS devices participants 
were also required to carry as well as survey 
development) 
One time cost to purchase the 
computer and software to run 
ACASI ($1500-$4000). Cost 
depends on number of questions and 
if translation is necessary. A 
dedicated computer is often required 
for ACASI surveys. Remuneration 
for participation 
Cost to attain and test sample varies by the 
number of drugs tested per patch. Price 
increases if repeated measures are required. 
Often, samples are processed in external 
labs. For EXACT: $540.00 for 50 patches, 
$25.00 for protective covers and $21.00 to 
test each patch. Per person: approximately 
$131 
Participant Burden and 
ramifications 
Participants must remember to report every 
occurrence of drug use or drug craving. It is 
expected participants will report daily and 
therefore with so many responses from each 
participant, the effect of missing or forgetting 
to report an event (or a few events) has less of 
a consequence on the ability to use the data to 
make accurate inferences 
Returning to the study site for each 
interview can be difficult for some 
participants, especially if they lack 
access to a car or are working. The 
ramifications of missing even a 
single study visit may affect data 
quality and the ability to make 
accurate inferences  
The patch must be worn 24 hours a day and 
may become uncomfortable. If the sweat 
patch is removed it cannot be put back on to 
resume drug metabolite capture. If the patch 
is tampered with, data concerning duration 
of drug use is lost.  
Possible 
biases/misclassification 
Social desirability bias and user fatigue. Over 
and under reporting of activities is likely and 
this is a common problem when asking 
participants to describe specific illicit 
behaviors. The use of devices for a long 
period of time may lead to user fatigue and 
attrition in reporting.  
Social desirability bias and recall 
Bias. Recall biases arise when 
cohort studies require participants to 
recall their drug using behaviors 
from the previous study visits 
(sometimes 6-months apart). This 
leads to under and over reporting 
behaviors 
The sweat patch may affect the behaviors of 
participants and therefore may not capture 
the true drug using history leading to 
misclassification biases 
How does this method 
overcome the possible biases? 
A hallmark of EMA data collection is ability 
to reduce social desirability bias by providing 
participants with devices in which they can 
report their drug use when it occurs in their 
natural environments outside of a study visit. 
User fatigue can be assessed and follow-up 
times adjusted to ensure participants report 
their behaviors 
The purpose of ACASI is to allow 
participants to answer questions 
concerning illicit behaviors using 
the computer rather than in a face-
to-face interview to reduce social 
desirability bias. Additionally 
because the survey is read aloud by 
the computer, literacy is not a 
concern. 
This method can not guarantee participant 
compliance 
Figure 5.1: Future directions of EMA and mHealth research 
Figure 5.1: EMA methods currently provide real-time data on an individual’s environment and behavior.  
A system that is unobtrusive and uses additional features of the phone as well as geo-tracking applications 
and biosensor technologies will provide an even deeper understanding of individual movement and 
behavior in real time, which can be used for ecological momentary interventions.   
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